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Abstract
Background: Mood and anxiety disorders are leading causes of disability and mortality, due largely to their onset
during adolescence and young adulthood and broader impact on functioning. Key factors that are associated with
disability and these disorders in young people are social and economic participation (e.g. education, employment),
physical health, suicide and self-harm behaviours, and alcohol and substance use. A better understanding of the
objective markers (i.e. neurobiological parameters) associated with these factors is important for the development
of effective early interventions that reduce the impact of disability and illness persistence.
Methods: We systematically reviewed the literature for neurobiological parameters (i.e. neuropsychology,
neuroimaging, sleep-wake and circadian biology, neurophysiology and metabolic measures) associated with
functional domains in young people (12 to 30 years) with mood and/or anxiety disorders.
Results: Of the one hundred and thirty-four studies selected, 7.6 % investigated social and economic participation, 2.
1 % physical health, 15.3 % suicide and self-harm behaviours, 6.9 % alcohol and substance use, whereas the majority
(68.1 %) focussed on clinical syndrome.
Conclusions: Despite the predominance of studies that solely examine the clinical syndrome of young people the
literature also provides evidence of distinct associations among objective measures (indexing various aspects of brain
circuitry) and other functional domains. We suggest that a shift in focus towards characterising the mechanisms that
underlie and/or mediate multiple functional domains will optimise personalised interventions and improve illness
trajectories.
Keywords: Depression, Anxiety, Bipolar, Functional outcomes, Biomarkers, Neurobiology, Neuropsychology,
Personalised psychiatry
Background
Depression and anxiety are associated with the greatest
burden of disease of all neurological, psychiatric and sub-
stance use disorders [1]. The early onset of psychiatric ill-
ness plays a key role in such disability with approximately
75 % of these disorders occurring before the age of 25
years [2]. Despite this, our current capacity to provide tai-
lored early interventions and prevent the progression of
illness or slow the pathway to disability is lacking [3].
Whilst, some specific diagnoses have been successfully
treated with certain interventions (e.g. CBT for social
anxiety disorder; [4]), there are limitations to the op-
timal treatment for unipolar, bipolar and comorbid
mood disorders. This is particularly evident for those
with emerging illnesses who often experience mixed
states and/or subthreshold symptoms [5]. Since these
mood states typically arise during adolescence and
young adulthood, a period of critical brain develop-
ment and functional independence, the impact of ill-
ness can lead to greater disability and worse illness
outcomes [6–8]. Thus, the search for objective
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markers of early risk states with predicative capacity
in regards to disability and mortality requires rigorous
investigation so that appropriate interventions can be
trialled and delivered as early as possible to reduce
the impact of disability [3, 9].
Traditionally, there has been a focus on the ‘clinical
syndrome’ defined as identifying distinct clinical cat-
egories or disorders (based on ICD or DSM diagnos-
tic criteria) with specific thresholds and the impact of
these on functioning. However, even at a subthreshold
symptom level significant contributors to disability
and mortality include social and economic disability
[10, 11], poor physical health (e.g. diabetes) [12], high
suicide and self-harm behaviours [10, 13–15], and
risky alcohol and substance use [16, 17]. Given the
clinical impact of these factors for young people with
emerging mood and anxiety disorders, we have identi-
fied them as key functional domains that, we argue,
should be the focus of targeted personalised assess-
ment and intervention. Although the term ‘functional
domain’ has traditionally, often referred to outcomes
relating to occupational (i.e. employment and educa-
tion) status, here, we use the term to include other
key factors that have significant (often concomitant)
impacts on levels of functioning in young people.
These domains largely align with the framework pro-
vided by the ‘International classification of function-
ing, disability and health’ [18] for conceptualising
health and health related states. These include: (i) so-
cial and economic participation (i.e. engagement and
stability in employment, education and social relation-
ships); (ii) physical health; (iii) suicide and self-harm
behaviours; (iv) alcohol and substance use; and (v)
clinical syndrome (i.e. diagnostic category, stage of ill-
ness and severity of symptoms [3]). These domains
are priority areas for service models in Australia (e.g.
headspace [19, 20]), which recognise the need for
early interventions that aim to target specific out-
comes associated with illness persistence and greater
disability [21]. Importantly, a focus on these five do-
mains recognises the need to evaluate multiple (often
interacting) aspects of an individual to better charac-
terise their specific phenotype and, as a result, at-
tempt to predict their potential illness trajectory.
To overcome some of the limitations associated
with current diagnostic approaches that link poorly to
neurobiological risk factors or patterns of treatment
response it is important to characterise the neurobiol-
ogy that may underlie or mediate observable func-
tional impairment(s) [9, 22]. This emphasises the
need to focus on the four remaining functional do-
mains in addition to the traditional focus on the clin-
ical syndrome to optimise personalised interventions.
Models of psychopathology suggest that breakdowns
in common brain circuits involved in cognition and
behaviour are responsible for the development of psy-
chopathology and general dysfunction [23]. In this
view, quantifying the integrity of such brain systems
(e.g. via neuroimaging, neurophysiology or circadian
biology) along with their behavioural concomitants
(e.g. neuropsychology, social cognition or sleep-wake
patterns) may lead to the identification of objective
markers of early risk states and also serve as treat-
ment targets. For example, in a longitudinal study by
our group, neuropsychological performance at base-
line was the single best predictor of socio-
occupational functioning at follow up, over and above
diagnosis and symptom severity [24]. Such findings
demonstrate the relevance of objective ‘brain’ markers
(in this case, a cognitive phenotype) to provide im-
portant insights about a crucial functional domain,
which cut across diagnostic categories to direct effect-
ive treatment strategies at the pathophysiological
driver of poor patient outcomes.
Here, we present a systematic review of the neuro-
biological and neurocognitive correlates, of five func-
tional domains in young people with mood and
anxiety disorders. We focus specifically on major
depression, bipolar disorder (I, II, not otherwise speci-
fied; NOS) and anxiety disorders (excluding post-
traumatic stress disorder), since these most closely
relate to the common developmental trajectories of
emerging mood disorders in young people [25]. In
this review we evaluate the relationship between the
functional domains (described above), and evidence
from neuropsychology, neuroimaging, sleep-wake and
circadian biology, neurophysiology and metabolic
studies. A wide age range was chosen (12–30 years)
to focus on the adolescent and young adult popula-
tion; referred to collectively as ‘young people’, to bet-
ter understand the primary age group that are
vulnerable and present to primary youth mental
health services. The primary objective of this study is
to establish the current status of the literature of
young people with mood and anxiety disorder with
respect to neurobiological investigations addressing
any of the proposed five functional domains. Whilst,
we expect that the large majority of identified studies
would investigate clinical syndromes and a smaller
number would investigate the remaining functional
domains, it is expected that unique associations be-
tween neurobiological parameters and a functional
domain, not accounted for by the clinical syndrome,
will become clearer. The aim of our approach is to
ultimately provide a framework for guiding the devel-
opment of personalised assessment and interventions
to prevent or delay significant disability in young
mental health patients.
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Methods
Methods of review regarding eligibility criteria, data
collection and synthesis were specified in advance in
the form of a review protocol. We followed the
guidelines for conducting and reporting a systematic
review set out by ‘the PRISMA statement’ [26], and
the ‘Cochrane Handbook for Systematic Reviews’ [27].
Eligibility criteria
Report characteristics and information sources
We searched PubMed databases for unique records
using the following criteria: (i) published in the last
20 years (i.e. between January 1994 and March, 2014,
to coincide with the release of DSM-IV since this ver-
sion introduced the use of clinical significance ratings
related to the impact of illness on areas of function-
ing); (ii) the study was reported in English; and (iii)
had keyword combinations (see Table 1 for full search
terms). The reference lists of studies identified by our
PubMed search were not utilised as an additional in-
formation source.
Study characteristics and selection
Using a pro forma, the first author (FI) checked the
abstract and/or full texts of each paper for the follow-
ing inclusion criteria; i) a mean age between 12 and
30 years; ii) at least one group of subjects was re-
ported as having a primary mood and anxiety (i.e. de-
pression, bipolar, anxiety) disorder (according to
DSM-IV or ICD-10 criteria) or syndrome (e.g. ‘at risk’,
current depressive symptoms); iii) at least one of the
following functional domains: (a) social and economic
participation; (b) physical health; (c) suicide and self-
harm behaviours; (d) alcohol and substance use; and/
or (e) clinical syndrome, was measured/quantified;
and iv) a statistical (i.e. correlational, regression, etc.)
association between the functional domain and at
least one neurobiological parameter (i.e. neuropsych-
ology, brain imaging, sleep-wake and circadian biol-
ogy, neurophysiology and metabolic) was reported.
Review articles and case studies were excluded from
the final synthesis. Studies were labelled ‘yes’ if they
fulfilled all four criteria, ‘no’ if they failed to meet all
four criteria or ‘possibly’ if it was unclear whether all
Table 1 Full list of search terms used according to each topic area
Topic area Pub Med Terms
Population of interest Mood and anxiety syndrome or profile Anxiety disorder OR anxiety OR depression OR depressive
disorders OR depressive disorder [MeSH Terms] OR major
depressive disorder OR MDD OR disorder, bipolar
[MeSH Terms] OR bipolar disorder OR affective disorder OR
mood disorder OR affective syndrome OR manic syndrome
OR depressive syndrome OR anxious syndrome
Youth Adolescents OR young people OR adolescence OR adolescent
[MeSH Terms] OR youth OR young adult
Functional domain Social and economic participation Socio-occupational functioning OR functioning OR social
functioning OR occupational participation OR economic
participation
Physical health Physical health OR metabolic rate OR obesity OR blood
pressure OR CVD OR fitness OR cardiovascular disease OR
BMI or body mass index OR waist measurement OR blood
glucose OR smoking rate OR physical activity OR cholesterol
levels
Suicide and self-harm behaviours Suicide [MeSH Terms] OR suicide ideation OR self-harm OR
suicide risk
Alcohol and substance use Substance use disorder [MeSH Terms] OR alcohol use OR
drug use
Clinical syndrome Illness progression OR syndrome progression OR symptom
severity
Neurobiological parameter Neuropsychology Neuropsychology OR neuropsychological test [MeSH Terms]
Imaging Brain imaging [MeSH Terms] OR imaging OR neuroimaging
OR fMRI OR DTI OR MRI OR MRS
Sleep-wake and circadian biology Actigraphy [MeSH Terms] OR melatonin secretion OR
circadian rhythms OR DLMO OR sleep-wake and circadian
biology
Neurophysiology Neurophysiology OR EEG OR electroencephalography OR
ERP OR event-related potentials
Metabolic BMI OR waist measurement OR blood pressure OR cholesterol
Note. Terms within each cell in column 3 (above) used the ‘OR’ function, whilst the ‘AND’ function was used to combine terms between the cells of column 3
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criteria were fully met. Any disagreement with these
rules was resolved by consensus with the senior au-
thor (DH).
Identification of studies
Figure 1 displays the series of steps undertaken as we
identified studies for this systematic review. First, of the
3975 studies identified by the searches (see Table 1 for
search terms), 565 titles and abstracts were examined for
eligibility. At this stage, 188 studies were excluded on
the basis of not meeting one or more of the eligibility
criteria specified. The eligibility stage involved the as-
sessment 377 full texts (i.e. the published manuscript) to
evaluate whether these studies were suitable, which led
to a further 243 studies being excluded. The remaining
134 studies were included in the final synthesis (see
Table 2 for a summary of these studies).
Synthesis of results
For each of the included studies, the reviewer (FI)
collated data with respect to the study design (i.e. cross-
sectional, longitudinal; see Table 2), sample characteris-
tics (i.e. age, sample sizes), aims, key measures (e.g.
neuropsychological, circadian, clinical) and key findings
(presented in Tables 3, 4, 5, 6 and 7; one table per
neurobiological parameter). To clarify, the key findings
for each study were taken as any evidence of an associ-
ation between a particular neurobiological measure and
a functional domain. In order to achieve this, the various
scales, tests, and assessments were collapsed into
broader categories of key measures (e.g. specific neuro-
psychological subtests grouped into a cognitive domain;
see Tables 3, 4, 5, 6 and 7). Given the variability in meth-
odology and the large and varied outcomes of identified
studies it was not appropriate to carry out a meta-
analysis [28].
Results
A total of 134 studies were included in this systematic
review (see Fig. 1); 10 of these studies were featured
more than once in the data synthesis to make a total of
144 reported results. As summarised in Table 2, the in-
cluded studies were categorized according to functional
domain in the following proportions: 7.6 % (k = 11) in-
vestigated social and economic participation, 2.1 % (k =
3) physical health, 15.3 % (k = 22) suicide and self-harm
behaviours, 6.9 % (k = 10) alcohol and substance use,
and 68.1 % (k = 98) clinical syndrome. In regards to
neurobiological parameters, 19.4 % (k = 28) focused on
neuropsychology, 43.1 % (k = 62) on neuroimaging, 16 %
(k = 23) on sleep-wake and circadian biology, 14.6 % (k =
21) on neurophysiology and 6.9 % (k = 10) on metabolic
measures. The range of the mean ages for patient groups
Fig. 1 This figure communicates the flow of studies through the systematic review process and identifies the number of studies excluded at
each phase as well as the reason for exclusion
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Table 2 Overview of the included studies organised according to functional domain and neurobiological parameter investigated
Neurobiological parameter
Functional domain Neuropsychology Imaging Sleep-wake and circadian biology Neurophysiology Metabolic
Social & economic participation Beiderman (2011) Perlman (2012) Abelson (1996) Kaur (2013) Taylor (2008)*
Fujii (2013)* Goodyer (1998)*
Korhonen (2002) Granger (1994)
Lee (2013c)
Lee (2013a)
Physical health Bond (2011) Jarworska (2011)* Mannie (2013)
Suicide & self-harm behaviours Bridge (2012) Ehrlich (2004) Coplan (2000)* Ashton (1994) Apter (1999)
Miranda (2012) Ehrlich (2005) Mathew (2003) Graae (1996) De Berardis (2013)
Ohmann (2008) Goodman (2011)* McCracken (1997)* Pechtel (2013) Plana (2010)
Oldershaw (2009) Pan (2011) Soreni (1999)
Pan (2013b)* Pan (2013a) Tyano (2006)
Pan (2013b)*
Alcohol & substance use Harvey (2007) Chitty (2013) Chitty (2014) Goldstein (2008)




Clinical syndrome Andres (2007) Adler (2007) Adam (2010) Bakker (2011) Pine (2001)
Andres (2008) Aghajani (2013) Ankers (2009) Carrasco (2013a) Taylor (2008)*
Basso (2001) Bitter (2011) Armitage (1997) Carrasco (2013b)
Cataldo (2005) Chang (2008) Coplan (2000)* Croarkin (2014)
Fleck (2008) Chu (2013) Doane (2013) Dai (2012)
Fujii (2013)* Diler (2013) Ellenbogen (2006) El Badri (2001)
Gunther (2004) Forbes (2006) Ellenbogen (2010) Hajcak (2008)
Han (2012) Forbes (2010) Goodyer (1998)* Houston (2003)
Kıvırcık (2003)* Gabbay (2012) Harkness (2011) Jarworska (2011)*
Klimkeit (2011) Gabbay (2013) Landsness (2011) Jarworska (2013)
Okasha (2000)* Gao (2013) McCracken (1997)* Kıvırcık (2003)*
Pavuluri (2010a) Gilbert (2000) Murray (2012) Okasha (2000)*
Schmid (2013) Gilbert (2009) Rao (1996) Stern (2010)
Simons (2009) Goodman (2011)* Rao (2008) Vaidyanathan (2014)
Torres (2010) Gruner (2012) Robillard (2013a)
Wall (2013) Hatton (2012) Robillard (2013b)
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across all the included studies was 11.7 to 31.7 years,
since those studies that had comparison groups both in-
side and outside the inclusion criteria of 12 to 30 were
still included.
Neuropsychology
There were 28 studies (a total of 2877 participants;
58.5 % female) that utilised neuropsychology and across
these studies 69 % (2037/2877) were patients and 29 %
(804/2877) were healthy controls. Among the patient
group 47 % (966/2037) had depression, 15 % (301/2037)
had bipolar, 12 % (239/2037) had anxiety, and 26 %
(531/2037) were classified as other.
Functional domains: social and economic participation,
physical health, suicide and self-harm & alcohol and
substance use
Our systematic search found an association between neuro-
psychology and three functional domains (i.e. social and
economic participation, suicide and self-harm and alcohol
and substance use). No studies that met our criteria
investigated physical health. The relationship between glo-
bal deficits in cognition and social and economic participa-
tion in mood disorders is unclear as there were only two
studies; one reporting a positive relationship [24], and the
other no relationship [29]. The former study utilised a
mixed psychiatric sample that consisted of mood disorder
and psychosis patients, which may have influenced the re-
sults given the well-supported relationship between social
and economic participation and neuropsychology in pa-
tients with psychosis [30]. However, the latter study only
investigated MDD (N = 16) and utilised the Global Assess-
ment of Functioning scale (GAF) as a measure of partici-
pation, which could be problematic as the rating can be
made on the basis of symptoms or functioning. Thus, it is
clear that more studies are needed in this population to
resolve or clarify such findings.
Studies exploring specific neuropsychological capabil-
ities have provided greater insight into how these relate
to functional domains that can be ambiguous when in-
vestigating global cognition. Of the neuropsychological
studies reviewed, executive function appears to be
Table 2 Overview of the included studies organised according to functional domain and neurobiological parameter investigated
(Continued)
Neurobiological parameter
























Note. * = indicates the study appears more than once, BOLD = longitudinal study, italicized = Study conducted by the Brain and Mind Centre
Clinical syndrome
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[40] HC: 13.6 ± 2.1, HC (47M; 34F), Evaluate the clinical
impact of executive
function deficits in youth
with BPD-I disorder.
NΨ: Executive function




function ~ ↓ social and
economic participationHC-EFD: 13.9 ± 2.3, HC-EFD (12M; 5F),
BPD-I: 13.7 ± 2.1, BPD-I (52M; 24F),
BPD-I-EFD: 12.8 ± 2.4 BPD-I-EFD (49M; 13F) Functional: GAF, WRAT-III,
placement in special class
[39]* SAD: 23.9 ± 6.7; SAD (20M; 10F) Assess the
neuropsychological
function of SAD without
co-morbidity
NΨ: Executive function
(CPT, TMT-B, WCST), Pro-
cessing speed (TMT-A),
Verbal learning & mem-
ory (AVLT)
SAD: ↓ executive
function ~ ↓ social and
economic participation
(and ↑ SAD severity)
HC: 25.6 ± 5.6 HC (20M; 10F)
Functional: GAF









S & V), Attention (WAIS-III-
DS, BD & DSp)
MDD: No significant ~ NΨ
HC: 16.9 ± 1.9 HC (11M; 14F) MDD: ↓ social and
economic participation
Functional: GAF
FED: 22.00 ± 4.9 FED (8M; 12F) Assess the effectiveness












ing and memory (Logical





FED & FEP: CR ~ ↑
immediate learning and
memory, and ↑ social
and economic
participation (mediated
by ↑ delayed learning
and memory)
FEP: 23.30 ± 3.9 FEP (20M; 13F)
Functional: SFS
[24] MHP: 21.6 ± 4.5 MDD (34) Identify cognitive markers
that predict later socio-
occupational functioning.






learning & memory (LM-
Ret, RAVLT-ret), Visual
learning & memory (CAN-
TAB- SSP;- PAL)
MHP: ↑ BL general NΨ
~ ↑ social and economic
participation at FUPBPD (29)
PSD (30)
(of the total 93,











SA: ↓ decision making ~
suicide attempt history
PC: 15.6 ± 1.4 PC (10M; 30F) Functional: CSHF, PSIS








SA: ↓ BL cognitive
inflexibility ~ ↑ suicide
ideation at 6-month FUP.NSA: 18.31 ± 0.78 NSA (9M; 23F)
Functional: BSS, SBS,
SHBQ






NSIB: 15.1 ± 1.4 NSIB (77)
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[33] HC: 15.8 ± 1.5 HC (11M; 46F) Assess decision making
and problem solving
ability in adolescents with
current or past self-harm
NΨ: Decision making (IGT,
MEPS)
DSH: ↓ decision making
~ current, but not past
DSH
PC: 15.7 + 1.3 PC (2M; 20F) Functional: Clinical
interview
DSH: 15.8 + 1.5 DSH (5M; 49F)
[34]* SA: 16.20 ± 0.78 SA (4M; 11F) Measure neural activity
during performance on
the IGT in adolescents.
NΨ: Decision making
(IGT-mod)
SA: ↑ decision making ~
suicide attempt history
PC: 15.79 ± 1.58 PC (7M; 7F) Functional: C-CASA, CSHF,
SIQ, SIS





CU (28M; 42F) Investigate the non-acute
relationship between can-
















on the working memory
and strategy measures
Functional: TLFB
[165] HC-NB: 22.9 ± 3.1 HC-NB (7M; 14F) Compare the cognition in
binge drinkers with













MDD-B: ↓ visual learning
& memory and overall
pattern of ↓ NΨ
functioning.
HC-B: 23.0 ± 2.5; HC-B (13M; 11F)
MDD-NB: 21.7 ± 3.2 MDD-NB (16M; 32F)














(WMS-III- LM1 & 2,
RAVLT), Visual learning
and memory (WMS-III: VR











HC: 13.81 ± 2.74 HC (18M; 17F)
Clinical: CDI, Y-BOCS
[51] OCD: 13.46 ± 2.83 OCD (16M; 13F) Explore the evolution of
cognitive dysfunction in
children and adolescents






(WMS-III- LM1 & 2,
RAVLT), Visual learning
and memory (WMS-III: VR









cognitive profile of the
OCD group was
normalized)
HC: 13.06 ± 2.84 HC (12M; 10F)
Clinical: Y-BOCS
Iorfino et al. BMC Psychiatry  (2016) 16:156 Page 8 of 38
Table 3 Neuropsychological studies evaluating the five functional domains in young people (12–30 yrs) with a mood and/or
anxiety disorder (Continued)
[53] OCD: 29.70 ± 10.74 OCD (12M; 8F) Examine the impact of
depression on executive
function deficits in OCD






depression severityHC: 30.06 ± 10.06 HC (11M; 21F)
Clinical: MMPI-D
[47] HC: 12.5 ± 2.4 HC (11M; 10F) Compare impulsivity at
the neuropsychological









DD: ↑ symptom severity
~ ↑ reaction time, ↓ in






Clinical: HDRS, CDI, CPRS-
R:L
[166] HC: 28.2 ± 7.9 HC (20M; 28F) Investigate the effect of





EUT: ↑ cognitive flexibility
than MEM. Performed
similarly to FEMEUT: 30.0 ± 7.2 EUT (11M; 14F)
FEM: 25.7 ± 9.2 FEM (11M; 10F) Clinical: YMRS, HDRS
MEM: 28.2 8.6 MEM (16M; 18F)
[39]* SAD: 23.9 ± 6.7; SAD (20M; 10F) Assess the
neuropsychological
function of SAD without
co-morbidity
NΨ: Executive function
(CPT, TMT-B, WCST), Pro-
cessing speed (TMT-A),
Verbal learning & mem-
ory (AVLT)
SAD: ↓ executive
function ~ ↑ SAD severity
HC: 25.6 ± 5.6 HC (20M; 10F)
Clinical: GAF












Attention (go-no go task)
DD: ↓ verbal learning and
memory compared to HC
and ANX.ANX: 12.4 ± 2.3 ANX (19M; 15F)
DD: 13.5 ± 2.6 DD (17M; 14F)
Clinical: CDI
[48] HC: 17.46 ± 1.59,
MDD: 17.32 ± 1.59























[167]* OCD: 27 ± 9.8 OCD (15M; 16F) Characterize the cognitive
functions of the patients










HC: 27.4 ± 9.1 HC (14M; 16F)
Clinical: HDRS










time task), Set shifting
(Local-global task) Clinical:
DD: ↓ WM & VF. MDD:
↓WM & processing speed
DD: 15.6 ± 1.5 DD (6M; 6F)
HC: 15.8 ± 1.2 HC (9M; 24F)
[52] OCD: 24.06 ± 5 OCD (21M; 9F) Assess the relationship
between cognitive
dysfunction, clinical status









HC: Matched HC (21M; 9F)
Clinical: YBOCS
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Table 3 Neuropsychological studies evaluating the five functional domains in young people (12–30 yrs) with a mood and/or
anxiety disorder (Continued)
abilities, overfocused at-
tention to irrelevant stim-
uli and delayed selective
attention to relevant
tasks. Mild cases showed
better selective attention
than severe cases. Obses-
sive cases had a defective
visual memory, while
compulsive cases had de-




both early and late.
[55] HC: 12.4 ± 3.3, HC (15M; 9F) Examine the treatment
impact of lamotrigine on
the neurocognitive profile






(WMS; DS, SS), Verbal
memory (CVLT)
BPD: ↑ Working memory
and verbal memory
following treatment (to
levels similar to HC)
BPD: 13 ± 3.1 BPD (18M; 16F)
Clinical: YMRS




(CWIT, TMT-B), Verbal flu-
ency (VFT), Processing
speed (TMT-A),
MDD: Poor BL inhibition
and switching ~ ↑ relapse
at FUHC: 26.93 ± 5.18 HC (14M; 14F)
Clinical: MADRS










CS: Poor BL episodic
memory ~ ↑ depressive
symptoms at FUP
Clinical: SCL-90
























HC: 22.5 ± 4.8 HC (12M; 13F)
Clinical: PANSS, HDRS,
BPRS, GAF, YMRS
[56] MDD: 16.2 ± 1.1 MDD (7M; 11F) Investigate the
neurocognitive outcome
in adolescents who were
treated with TMS










Note. Sample: ANX Anxiety disorder, BPD Bipolar Disorder, BPD-I Bipolar Disorder I, BPD-I-EFD Bipolar Disorder I with Executive Function Deficits, CS Community
Sample, DD Depressive disorder, CU Cannabis user, DSH Deliberate Self-Harm, EUT euthymic, FED First-Episode depression, FEM first episode mania, FEP First-
Episode Psychosis, HC Healthy Controls, HC-B Healthy Control Binge drinker, HC-EFD Healthy Control with Executive Function Deficits, HC-NB Healthy Control Non
Binge drinker, MDD Major Depression Disorder, MDD-B Major Depression Disorder Binge drinker, MDD-NB Major Depression Disorder Non Binge drinker, MEM
multiple episode mania, MHP Mental Health Patients (mixed diagnosis sample), NSA No Suicide Attempt, NSIB No Suicide Ideation Behaviour, OCD Obsessive
Compulsive Disorder, PC Psychiatric Control (i.e. psychiatric diagnosis but no suicide attempt), PSD Psychotic Spectrum Disorder, SA Suicide Attempters, SAD Social
Anxiety Disorder, SIB Suicide Ideation Behaviour
Measures: ANT Attention network test, AUDIT Alcohol Use Disorder Identification Test, AVLT Auditory Verbal Learning Test, BDI Beck Depression Inventory, BPRS
Brief psychiatric rating scale, BSS Beck Scale for Suicidal Ideation, CANTAB Cambridge Neuropsychological Test Automated Battery [subsets include: FAS Fluency
and semantic test, IED Intra/Extra dimensional Set Shift Errors, MS Motor Screening, PAL Paired associates learning, PRM Pattern recognition memory, RVP Rapid
Visual Processing hits score, SRM Spatial recognition memory, SSP Spatial span task, SWM Spatial working memory), C-CASA Columbia Classification Algorithm of
Suicide Assessment, CDI Children’s Depression Inventory, COWAT Controlled Oral Word Association Task, CPRS-R:L Conners Parent Rating Scale- Revised: Long
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particularly associated with social and economic partici-
pation as well as suicide and self-harm behaviours. More
specifically, three of the five included studies have shown
decision-making and conceptual flexibility impairments to
be predictive of suicide and self-harm behaviours [31–33].
Taken together, these studies identify a shared pathophysi-
ology among those who have previously attempted suicide,
those who were current suicide attempters and those who
were currently self-harming; that is, they all showed char-
acteristic deficits in decision-making and cognitive inflex-
ibility. There is also contrary evidence whereby suicide
attempters performed better on the decision making task
than depressed patients who hadn’t attempted suicide and
healthy controls [34], and there were no neuropsycho-
logical differences between self-harmers and non-self-
harmers [35]. However, these findings may be attributed
to methodological differences and/or a modest sample
size, especially since the latter study [35] did not distin-
guish between current self-harmers and previous self-
harmers. The notion that impaired decision making and
conceptual flexibility may predispose one to suicidal be-
haviours is supported by evidence showing neurobiological
changes in the areas thought to subserve these functions.
Namely, structural and functional dysfunction in the orbi-
tofrontal prefrontal cortex have been identified which
imply that suicidal behaviour may be associated with defi-
cits in the attribution of importance to stimuli [36–38], al-
though changes in other regions, such as the dorsolateral
prefrontal cortex, have been implicated as well [38].
Similar deficits in executive function, particularly in
conceptual flexibility, was associated with impaired so-
cial and economic participation [39, 40], whereas studies
that investigated verbal learning and memory reported
conflicting results regarding social and economic partici-
pation. Two studies [24, 41] identified a positive rela-
tionship with this functional domain, whilst another two
studies did not find any association [29, 39]. Notably, lo-
gical memory retention (an index of structured learning
and memory) was a common measure identified as sig-
nificant in the positive studies, but it was not utilised in
the other two studies; additional studies of structured
learning and memory are needed however the evidence
to date suggests that there may be an important role for
this particular neuropsychological domain with regards
to social and economic participation.
Functional domain: clinical syndrome
The association between cognitive function and the clin-
ical syndromes of mood and anxiety disorders in adoles-
cents and young adults has previously been reviewed
extensively (see [42, 43]), and some of the findings of
such reviews have been reiterated by the present system-
atic review (see below). Interestingly, it has been re-
ported that impaired verbal memory is significantly
associated with depression (not specified as MDD) [44]
as well as the development of depressive symptoms, in a
community sample [45]. These findings implicate a dys-
function in memory occurring earlier in the course of
depressive syndrome development while, poor executive
function may be associated with more persistent MDD
[46]. In terms of delineating symptom severity, individ-
uals diagnosed with unipolar depression with higher
levels of depressive symptoms also show increased (i.e. de-
layed) choice reaction time [47], lower cognitive control of
emotional processing [48], and processing speed deficits
[49] suggesting that a broader range of cognitive (includ-
ing social) measures are also associated with depression
and may also be sensitive to the severity of illness.
Similar deficits in cognition have been observed
among those with anxiety disorders. Greater Social Anx-
iety Disorder (SAD) symptom severity was associated
with poor executive function, specifically cognitive in-
flexibility in SAD patients [39]. Most studies have identi-
fied cognitive deficits associated with OCD, such as,
impaired verbal and visual memory [50], information
processing [51, 52], and cognitive flexibility [51–53]. As
observed in unipolar depression, increased symptom
severity in those with OCD is associated with worse
selective attention [52], however this has also not been
uniformly reported [50]. Comorbidity has been identi-
fied as another factor related to the cognitive deficits
in OCD, whereby comorbid depression was associated
Version, CPT Continuous Performance Test, CSHF Colombia Suicide History Form, CST Concept shifting test, CVLT California Verbal Learning Test for Children,
D-KEFS Delis–Kaplan Executive Function System, GAF Global Assessment of Functioning, HDRS Hamilton depression rating scale, IGT Iowa Gambling Task, K-BIT
Kaufman Brief Intelligence Test, LDSB Longest Digit Span Backward, LDSF Longest Digit Span Forward, LDST letter digit substitution test, LM-Ret logical memory-
percentage retention, MADRS Montgomery-Asberg Depression Rating Scale, MEPS means-ends problem-solving procedure, MFFT matching familiar figures test,
MMPI-D Minnesota Multiphasic Personality Test, depression subscale, NAART North American Adult Reading Test, NΨ neuropsychological, PANSS positive and
negative syndrome scale, PSIS pierce suicide intent scale, RAVLT rey auditory verbal learning test; total score; retention; and/or 20min score, RCF Rey-Osterrieth
Complex Figure, SBS Suicide Behavior Screening, SCWT stroop colour and word test, SCL-90 symptom checklist, SCWT stroop colour and word test, SDMT symbol
digit modality test, SFS social functioning scale, SHBQ self-harm behavior questionnaire, SIQ suicide ideation questionnaire, SIS suicide intent scale, SOFAS social
and occupational functioning assessment scale, = time-line followback, TMT-A trail making test – part A, TMT-B trail making test – part B, VFT verbal fluency task,
WAIS-III Wechsler Adult Intelligence Scale [subsets include: S similarities, V Vocabulary, DS Digit symbol, BD Block design, FFD freedom from distractibility], WASI
Wechsler abbreviated scale of Intelligence, WISC Wechsler Intelligence Scale For Children, WCST Wisconsin Card Sorting Test, WDWT Walk don’t-walk test, WMS
Wechsler Memory Scale [subsets include: DS Digit Span, LM logical memory 1 & 2, SR = story recall, LLT List Learning Test, SS Spatial span, VR Visual Reproduction],
WRAT-III wide range achievement test – third edition, WTAR wechsler test of adult reading, Y-BOCS Yale–Brown obsessive-compulsive scale, YMRS young mania
rating scale
Findings: ↑ = Increased, Improved or Higher, ↓ = Decreased, Reduced or Lower, ~ = ‘is associated with’, FUP follow-up
*indicates that the study features more than once in the data synthesis
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[57] MDD: 15.7 ± 1.5; MDD (8M; 6F) Assess amygdala activation and
connectivity during an emotional
regulation task.
Imaging: fMRI MDD: ↓ amygdala–seeded
connectivities ~ ↓ social and
economic participationHC: 15.1 ± 1.6 HC (8M; 6F) Functional: CGAS
Physical
health
[58] BPD-O: 23.8 ± 4.5 BPD-O (9M; 11F) Examine the relationship between BMI
and brain volumes in mania.
Imaging: sMRI BPD: ↑ BMI ~ ↓ WMV and
TLV
BPD-N: 22.2 ± 4.4 BPD-N (19M; 18F) Functional: BMI HC: ↑ BMI ~ ↓ TBV and GMV.
HC-O: 22.0 ± 3.8 HC-O (12M; 5F)
HC-N: 22.3 ± 3.5 HC-N (19M; 19F)
Suicide and
self-harm
[170] MHP: 14.6 ± 3.4 PSD (18M; 5F) Compare WMH in psychiatrically
hospitalized youth with and without a
history of suicide attempt
Imaging: sMRI MDD: ↑ WMH~ suicide





[171] MDD: 26.7 ± 5.5 MDD (34M; 68F) Compare the prevalence and location
of WMH in young MDD inpatients
with and without histories of suicide
attempts
Imaging: sMRI MDD: ↑ PVH, not DWMH, ~
suicide attempt history, but
not ideationFunctional:
Clinical records
[59]* HC: 16.2 ± 0.8 HC (4M; 9F) Evaluate the ACC volumes of MDD/
borderline personality patients with
and without a suicide attempt history
Imaging: sMRI MDDx: ↓ BA24 volumes ~ ↑
number of suicide attempts
(and ↑ borderline severity,
but not depression)
MDDx: 15.8 ± 1.1 MDDx (2M; 11F) Functional:
Clinical interview
[62] SA: 16.20 ± 0.78
PC: 15.87 ± 1.55
HC: 15.21 ± 1.42
SA (4M; 11F) Evaluate the association between
neural activity during performance of
the go no-go task and suicide history.
Imaging: fMRI PC: ↑ activity in right ACG
compared to SA (but SA not
different from HC)PC (7M; 8F) Functional: CSHF
HC (8M; 6F)
[60] SA: 16.21 ± 0.80 SA (4M; 10) Measure neural activity during
processing of emotional faces in
adolescents with a history of
depression and suicide attempt
Imaging: fMRI SA: ↑ dorsal ACG activity
when viewing angry faces,
and ↓ visual, sensory,
prefrontal, ACG activity to
intense happy and neutral
faces ~ suicide attempt
history.
PC: 15.87 ± 1.55 PC (7M; 8F) Clinical: C-CASA,
CSHF, SIQ, SIS
HC: 15.27 ± 1.39 HC (8M; 7F)
[34]* SA: 16.20 ± 0.78 SA (4M; 11F) Measure neural activity during
performance on the IGT in
adolescents.
Imaging: fMRI PC: ↑ hippocampal activity
compared to HC. (HC and
SA did not differ, evidence
of ↓ activation)
PC: 15.79 ± 1.58 PC (7M; 7F) Functional: C-
CASA, CSHF, SIQ,
SISHC: 15.15 ± 1.46 HC (8M; 5F)
Alcohol and
substance use
[172] BPD-L: 23.7 ± 3.6 BPD-L (14M; 5F) Assess the effects of alcohol use on
GSH in young people with BPD.
Imaging: MRS BPD-H: ↓ GSH
BPD-H: 23.4 ± 3.1 BPD-H (12M; 2F) Functional:
AUDIT
HC: 23.6 ± 2.8 HC (13M; 4F)
[65] MDD: 21.7 ± 2.0 MDD (5M; 1F) Examine the effect of cannabis use on
threat-related amygdala reactivity.





[66] AUD: 17 ± 2.1 AUD (8M; 6F) Compare prefrontal-thalamic-
cerebellar measures of adolescents
and young adults with adolescent-
onset alcohol use disorders
Imaging: sMRI AUD: ↓ PFC & PFC WMV.
HC: 16.9 ± 2.3 HC (16M; 12F) Fucntional: ACQ,
LHAUI, SCID
AUD: ↓ PFC GM~ ↑ alcohol
consumption
AUD(M): ↓ CV
PFC volume variables ~
measures of alcohol
consumption
[64] BPD: 16 ± 2, BPD (5M; 9F) Compare brain morphometry in
bipolar adolescents with co-occurring
substance and alcohol disorders
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[63] CU: 18 ± 0.7 CU (12M; 4F) Examine the relationship between
brain volumes, depression and
cannabis use.
Imaging: sMRI CU: ↓ WMV ~ ↑ depressive
symptoms





[173] BPD: 19.9 ± 7.9 BPD (15M; 18F) Explore structural brain changes in
first-episode bipolar patients
Imaging: VBM BPD: ↑ volume in left
thalamus and fusiform and
cerebellum bilaterally. ↑ AC,
PPS GMD. ↑ middle/superior
temporal and posterior
cingulate gyri, GMV & GMD.
HC: 21.5 ± 4.3 HC (19M; 14F) Clinical: SCID,
KSADS
[90] DD: 15.6 ± 1.4, DD (4M; 21F) Investigate WM microstructure in a
sample of clinically depressed
adolescents relative to matched
controls.
Imaging: DTI DD: ↓ FA and ↑ RD, MD in
corpus callosum. ↑ FA & AD,
and ↓ RD in uncinate
fasciculus.
HC: 14.7 ± 1.6 HC (3M; 18F) Clinical: ADIS,
CDI, CBCL,
RCADS, YSRS
[46] BPD: 15.8 ± 1.8 BPD (6M; 11F) Compare amygdala
neurodevelopment among BPD,
ADHD, and healthy adolescents
Imaging: sMRI BPD: ↑ BL amygdala
volumes ~ symptomatic
recover compared to those
who did not achieve
recovery. No increase in
amygdala volume over time.
ADHD: 16.3 ± 1.7 ADHD (13M; 11F) Clinical: KSADS,
LIFE, YMRS,
HDRSHC: 16.3 ± 1.8 HC (13M; 10F)
[85] BPD: 15.9 ± 1.4 BPD (4M; 4F) Evaluate the effect of lamotrigine
treatment on amygdalar activation
Imaging: fMRI BPD: clinical improvement
~ ↓ right amygdalar
activationClinical: CDRS
[99] BPD: 25 ± 9 BPD (7M; 14F) Investigate the distribution of lactate
in bipolar and healthy brains
Imaging: MRS BPD: ↑ Lac/NAA & Lac/Cr
ratio
HC: 25 ± 6 HC (5M, 5F) Clinical: SCID
[174] BPD: 15.6 ± 0.9 BPD (2M; 8F) Explore the neural correlates of
depression at baseline and after 6
weeks of open as usual treatment
Imaging: fMRI BPD: After treatment, ↓ left
occipital cortex activity in
the intense fearful
experiment, but ↑ left insula,
left cerebellum, and right
ventrolateral PFC in the
intense happy experiment. ↑
improvement in depression
~ ↑ BL activity in ventral ACC
to mild happy faces
HC: 15.6 ± 1.2 HC (2M; 8F) Clinical: KSADS,
CDRS, SCARED,
YMRS
[175] MDD: 14.73 ± 1.49 MDD (3M; 11F) Examine behavioral and neural
responses to reward in young people
with depressive disorders using a
reward decision-making task
Imaging: fMRI MDD: ↓ activation in the





HC: 14.45 ± 1.79 HC (7M; 10F) Clinical: KSADS,
CBCL, SCARED,
CDI, BDI
[176] MDD: 12.9 ± 2.3 MDD (4M; 9F) Evaluate reward-related brain function
as a predictor of treatment response
in adolescents with MDD





~ ↑ clinical severity, ↓ anxiety
symptoms and faster
improvement in anxiety
symptoms after treatment. ↑






[68] MDD: 16.7 ± 2.7 MDD (9M; 12F) Test whether ACC GABA levels are
decreased in adolescents with MDD
Imaging: MRS,
sMRI
MDD & HC: ↑ ACC GABA ~ ↓
anhedonia scores.
HC: 16.2 ± 1.6 HC (6M; 15F) Clinical: KSADS,
CDRS-R, BDI
MDD: ↓ ACC GABA, ↓ ACC
WM
[177] MDD: 17.1 ± 2.5 MDD (9M; 12F) Assess striatum-based circuitry in rela-
tion to categorical diagnosis of MDD
and anhedonia severity
Imaging: fMRI MDD: ↑ iFC between all
striatal regions bilaterally
and DmPFC, RVC and ACC.HC: 16.3 ± 1.4 HC (9M; 12F) Clinical: KSADS,
CDRS-R, BDI
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MDD severity ~ iFC between
the striatum and the
precuneus, posterior






[178] BPD: 15.1 ± 1.81 BPD (6M; 12F) Investigate the brain structural
changes in BPD children and
adolescents
Imaging: DTI BPD: ↓ GMV in left
hippocampus. ↓ FA value in
rACC.HC: 14.1 ± 1.61 HC (6M; 12F) Clinical: KSADS,
YMRS, MFQ
↓ hippocampal volume ~ ↑
YMRS score
[91] OCD: 12.35 ± 2.93 OCD (7M; 14F) Measure neuroanatomical changes in
the thalamus of patients with OCD
near the onset of illness, and before
and after treatment.
Imaging: MRI OCD: ↑ thalamic volumes in





HC: 12.47 ± 8.33 HC (7M; 14F) Clinical: KSADS,
YBOCS, HDRS
↓ thalamic volumes ~ ↓ OCD
symptom severity
[179] OCD: 13.1 ± 2.5 OCD (11M; 7F) Examine whether overlapping but
symptom dimension-specific neural
activity patterns in adults are apparent
in youths
Imaging: fMRI OCD: ↓ activity in right
insula, putamen, thalamus,
dorsolateral prefrontal cortex
and left orbitofrontal cortex,
and right thalamus and right
insula. ↑ OCD symptom
related measures were
significantly predictive of ↓




HC: 13.6 ± 2.4 HC (11M; 7F) Clinical: YBOCS
[59]* HC: 16.2 ± 0.8 HC (4M; 9F) Evaluate the ACC volumes of MDD/
borderline personality patients with
and without a suicide attempt history
Imaging: sMRI MDDx: ↓ BA24 volumes ~ ↑
borderline severity, but not
depressionMDDx: 15.8 ± 1.1 MDDx (2M; 11F) Clinical: Clinical
interview
[94] OCD: 14.3 ± 2.1 OCD (13M; 10F) Investigate white matter abnormalities
in pediatric obsessive-compulsive
disorder.
Imaging: DTI ODD: ↑ FA in splenium ~ ↑
obsession severity
HC: 14.2 ± 2.2 HC (12M; 11F) Clinical: YBOCS,
KSADS
[180] MHP: 22.3 ± 3.7 MHP (50M; 83F) Examine the relationship between
anterior insula GMV, clinical symptom
severity and neuropsychological
performance.
Imaging: sMRI MHP: ↓ GMV in left anterior
insula. Changes (↑ or ↓) in
right anterior insula GMV ~ ↑
symptom severity.
HC: 23.8 ± 2.4 HC (13M; 26F) Clinical: BPRS,
HDRS, SOFAS
[95] MDD: 16.8 ± 2.2 MDD (9M; 8F) Investigate WM microstructure
in MDD using diffusion tensor imaging
Imaging: DTI MDD: ↓ WM integrity in the
genu of corpus callosum,
anterior thalamic radiation,
anterior cingulum and
sagittal stratum ~ ↑
depression severity.
HC: 16.4 ± 1.4 HC (6M; 10F) Clinical: KSADS,
BDI, CDRS-R,
MASC
[181] MDD: 15.8 ± 1.4 MDD (8M; 11F) Investigate sgACC FC in adolescent
depression during negative emotional
processing.





frontal gyrus functional con-
nectivity. ↓ sgACC-precuneus
functional connectivity ~ ↑
depression severity.
HC: 16.1 ± 1.2 HC (8M; 11F) Clinical: BDI
[93] HC: 16 ± 2.74 HC (6M; 7F) Evaluate whether the observed WM
disruptions are associated with
Imaging: DTI MDD at FUP ~ ↓ FA in the
superior longitudinal fasciculi
Iorfino et al. BMC Psychiatry  (2016) 16:156 Page 14 of 38





& the right cingulum-
hippocampal Projection.
SUD at FUP ~ ↓ FA in the
right cingulum-hippocampal
projection.




[182] OCD: 13.95 ± 2.52 OCD (9M; 16F) Investigate the development of the
ACC and its associations with
psychopathology.
Imaging: fMRI OCD: ↑ ACC activity during
error responses in bilateral
insular cortex during high
conflict tasks
HC: 13.71 ± 2.85 HC (9M; 16F) Clinical: YBOCS,
ADIS, CDI, STAI-
C, CBCL
[81] OCD: 13.78 ± 2.58 OCD (11M; 18F) Identify differences in regional brain
volume between medication-free
pediatric OCD patients and controls
and examine changes after cognitive
behavioural therapy
Imaging: VBM OCD: ↑ Orbitofrontal GMV
after treatment ~ ↑ symptom
improvementHC: 13.6 ± 2.73 HC (11M; 18F) Clinical: YBOCS,
ADIS, CDI, STAI-
C, CBCL
[183] BPD-I: 14.57 ± 1.98 BPD-I (11M; 7F) Examine patterns of activity and
connectivity in youth with BPD.
Imaging: fMRI BP-I: ↑ activity in amygdala
and VMPFC regulation
regions to happy faces and
reduced DLPFC activity to
fearful faces compared to
HC. BPD-NOS: ↓ PFC activity




BPD-NOS (11M; 7F) Clinical: KSADS,
MFQ, SCARED,
CALS
HC: 13.67 ± 2.55 HC (7M; 11F)
[71] HC: 23.9 ± 2.3 HC (12M; 21F) Evaluate patterns of grey matter
changes very early in the course of
affective illness compared to those
with discrete disorders and/or illness
persistence
Imaging: sMRI ST-2/3: ↓ GMV in frontal
brain regions
ST-1: 20.4 ± 5.2 ST-1 (8M; 15F) Clinical: HDRS,
SOFAS, BPRS
ST-2/3: 23.5 ± 3.5 ST-2/3 (14M; 10F)
[96] HC: 23.82 ± 2.52 HC (15M; 24F) Examine the association between
microstructural WM changes and
different stages of psychiatric illness.
Imaging: DTI ST-2/3: ↓ FA within the left
anterior corona radiata
compared to HC.ST-1B: 21.36 ± 3.51 ST-1B (24M; 49F) Clinical: HDRS,
BPRS, SOFAS
ST-1B: pattern of ↓ FA within
the left anterior corona
radiate (less WM
involvement than ST-2/3)
ST-2/3: 22.45±4.35 ST-2/3 (37M; 32)
[92] BPD: 23.03 ± 5.04 BPD (23M; 35F) Examine WM microstructural changes
in BPD.
Imaging: DTI BPD: ↓ FA in the genu, body
and splenium of the corpus
callosum as well as the
superior and anterior corona
radiata. ↑ radial diffusivity.
HC: 24.05 ± 2.92 HC (12M; 28F) Clinical: HDRS,
YMRS, SOFAS,
BPRS
[184] OCD: 13.1 ± 2.7 OCD (7M; 5F) Investigate possible regional brain
dysfunction in premotor cortico-
striatal activity, correlate brain activa-
tion with severity of obsessive-
compulsive symptomatology; And, de-
tect possible changes in brain activity
after pharmacological treatment
Imaging: fMRI OCD: ↑ activation bilaterally
in the middle frontal gyrus.
Clinical improvement
following pharmacological
treatment ~ ↓ activation in
left insula and left putamen
HC: 13.7 ± 2.8 HC (7M; 5F) Clinical: ChIPS, Y-
BOCS, CDI, STAI-
C, LOI-CV
[98] OCD: 12.5 ± 2.9 OCD (6M; 5F) Measure neurometabolite
concentrations in anterior cingulate-
medial frontal cortex and right and left
striatum of drug naïve children and
adolescents with OCD
Imaging: MRS OCD: ↓ total Cho in left
striatum (this ↓ did not
change over time and
persisted at follow-up
Assessment)
HC: 14.5 ± 2.8 HC (5M; 7F) Clinical: Y-BOCS,
CDI, STAI-C, LOI-
CV
[185] BPD: 27 ± 10 BPD (26M; 32F) Assess changes in GMV in BPD. Imaging: sMRI BPD: ↑ GMV in portions of
the VLPFC and hippocamps
complex. ↑ GMV in
amygdala proper and
caudate. ↑ number of
depressive episodes ~ ↑ GMV
in the right cingulate gyrus
bilaterally and right
thalamus and bilateral
lenticulate nuclei, and left
cerebellar vermis. ↑ illness
HC 27 ± 10 HC (21M; 27F) Clinical: SCID,
KSADS
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duration ~ ↓ GMV in left
cerebellar vermis.
[83] OCD: 12.79 ± 2.64 OCD (10M; 21F) Measure pituitary gland volume in
OCD
Imaging: MRI OCD: ↓ pituitary gland
volume ~ ↑ compulsive
symptom severity (more
pronounced in males).
HC: 12.89 ± 2.66 HC (10M; 21F) Clinical: YBOCS,
HAMA, HDRS
[74] MDD: 8 – 17years MDD (10M; 13F) Examine temporal lobe anatomy in
pediatric patients with MDD near the
onset of illness before treatment
Imaging: MRI MDD: ↑ left and right
amygdala: hippocampus
volume ratios ~ ↑ severity of
anxiety (but not ↑
depression severity or
duration of illness)
HC: 8–17 years HC (10M; 13F) Clinical: CDRS-R,
HAMA
[87] ANX: 11.8 ± 1.8 ANX (6M; 6F) Examine the relationships between
pretreatment amygdala activity and
treatment response in a sample of
anxious children and adolescents
Imaging: fMRI ANX: ↑ left amygdala
activation pre-treatment ~
treatment response to CBT
or medication. (no associ-
ation between pre-treatment




[78] SAD: 21.80 ± 3.68 SAD (14M; 6F) Explore the GMD deficits in drug-naïve
adult SAD patients
Imaging: VBM SAD: ↓ GMD in bilateral
thalami, right amygdala, and
right precuneus. ↓ right
amygdala GMD ~ ↑ disease
duration and ↓ age of onset.
HC: 21.58 ± 3.72 HC (13M; 6F) Clinical: HAMA,
HDRS, LSAS,
SCID
[69] DD: 15.4 ± 1.5 DD (3M; 23F) Examine GMV in brain areas putatively
involved in affective psychopathology.
Imaging: VBM DD: ↓ bilateral dorsal ACC
volume. No association with
clinical severity of
depression or anxiety.
HC: 14.7 ± 1.5 HC (3M; 23F) Clinical: ADIS,
CDI, RCADS, YSR,
CBCL
[100] BPD: 15.5 ± 1.5, BPD (5M; 23F) Compare in vivo neurometabolite
concentrations in bipolar adolescents
with a depressed episode
Imaging: MRS BPD: ↑ NAA in the ACC and
VLPFC. ↑ Cho and Cr in the
VLPFC.HC: 14.6 ± 1.8 HC (4M; 6F) Clinical: KSADS,
CDRS-R
[186] BPD: 14.3 ± 1.1 BPD (6M; 11F) Investigate the effects of
pharmacotherapy on brain function
underlying affect dysregulation and
cognitive function in pediatric bipolar
disorder.
Imaging: fMRI BPD: YMRS improvement ~ ↓
VMPFC activity.
Normalization of activity in
the inferior frontal gyrus
following pharmacological
treatment.
HC: 14.1 ± 2.4 HC (7M; 7F) Clinical: YMRS,
KSADS, CDI,
CDRS-R
[187] BPD: BPD (16M; 8F) Determine the relative effects of
risperidone and divalproex on brain
function in pediatric mania
Imaging: fMRI BPD: Divalproex treatment
~ ↑ activity in left MPFC
relative and modulation of
positive emotions to
risperidone. ↑ pre-treatment
right amygdala activity with
negative and positive condi-
tion in the risperidone
group, and left amygdala
with positive condition in
divalproex group predicted
poor response on YMRS.
HC: 13.9 ± 3.4 HC (7M; 7F) Clinical: KSADS,
CDRS, YMRS
[86] gSP: 25.91 ± 5.50 gSP (8M; 13F) Examine the change in amygdala-
insula-medial frontal function during
perception of social threat cues before
and after SSRI treatment
Imaging: fMRI gSP: SSRI treatment ~ ↓
amygdala reactivity to fearful
faces (which was ↑ pre-
treatment) and ↑ ventral
MPF activity to angry faces




HC: 26.95 ± 8.11 HC (10M; 9F) Clinical: SCID,
LSAS, HDRS, BDI,
STAI




Imaging: PET OCD: ↓ rCBF in OFC and ↑
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[70] HC: 17.19 ± 1.87 HC (7M; 9F) Investigate the role of dysregulation of
frontal-limbic circuits in the sympto-
mology of this disorder
Imaging: sMRI MDD: ↑ right and left rostral
MFG, and left caudal anterior
cingulate cortex thickness. ↑
age ~ ↓ left MFG thickness.
MDD: 16.89 ± 2.01 MDD (9M; 21F) Clinical: CDRS,
KSADS, BDI
[84] OCD: 12.70 ± 3.11 OCD (13M; 8F) Investigate the regional morphology
of the CC in OCD.
Imaging: sMRI OCD: ↑ corpus callosum
(except the isthmus). ↑ CC
area, genu, anterior body,
posterior body, isthmus and
anterior splenium ~ ↑
compulsive symptom
severity
HC: 12.74 ± 3.12 HC (13M; 8F) Clinical: YBOCS,
HAMA, HDRS,
KSADS
[79] OCD: 12.89 ± 3.23 OCD (5M; 6F) Evaluate neuroanatomic changes in
the thalamus of OCD patients near
illness onset before and after cognitive
behavioral therapy
Imaging: sMRI OCD: No significant change




[73] MDD: 15.35 ± .34, MDD (3M; 17F) Examine amygdala and hippocampus
volumes in pediatric MDD.
Imaging: sMRI MDD: ↓ left and right
amygdala volumes. No
correlations with symptom
severity, age of onset or
illness duration.
HC: 14.08 ± .31 HC (8M; 16F) Clinical: HDRS,
FH-RDC, KSADS
[75] GAD: 22.9 ± 4.1, GAD (16F) Investigate the neural substrates
associated with excessive and
persistent worrying in GAD
Imaging: sMRI GAD: ↑ amygdala and
DMPFC volumes. ↑ symptom
severity ~ ↑ DMPFC and ACC
volumes
HC: 23.7 ± 3.7 HC (15F) Clinical: SCID,
BDI, MCQ
[189] BPD: 14.6 ± 2.2 BPD (11M; 12F) Examine the neurofunctional effects of
ziprasidone in manic adolescents
Imaging: fMRI BPD: Ziprasidone treatment
~ ↑ in right BA 11 and 47
activation. No association
with symptom
improvement. ↓ BL right BA
47 activation ~ ↑
improvement of YMRS score.
HC: 15.0 ± 1.8 HC (6M; 4F) Clinical: YMRS,
CGI, KSADS
[101] BPD-R: 15.4 ± 1 BPD-R (4M; 3F) Evaluate the in vivo effects of
extended-release divalproex sodium
on the glutamatergic system in ado-
lescents with BPD and neurochemical
predictors of clinical remission.
Imaging: MRS BPD-r: ↓ BL Glx in LVLPFC.
Change in LVLPFC Glu ~
change in YMRS scoreBPD-NR: 14.1 ± 2.2 BPD-NR (6M; 1F) Clinical: KSADS,
CDRS, CGI, YMRS
HC: 14.4 ± 1.6 HC (6M; 9F)
[88] BPD-RE: 13.5 ± 2.4 BPD-RE (13M; 9F) Determine functional connectivity
among patients with pediatric BPD
who are responders to
pharmacotherapy and those who are
nonresponders,
Imaging: fMRI BPD-RE: ↑ connectivity of
the amygdala before and
after treatment compared to
BPD-NRE. ↑ right amygdala
functional connectivity after




BPD-NRE (6M; 6F) Clinical: KSADS,
YMRS, CDRS-R
HC: 14.2 ± 3.1 HC (7M; 7F)
[72] MDD: 28.8 ± 10.7 MDD (35M; 30F) Evaluate the early effects of
antidepressant therapy, as well as of
key clinical variables, on ACC volume
Imaging: sMRI MDD: >3 untreated
depressive episodes ~ ↓
subcallosal gyrus volumes
compared to HC.
HC: 28.4 ± 10.7 HC (37M; 56F) Clinical: YMRS,
GAF, HDRS, SCID
[82] OCD: 16.6 ± 1.5 OCD (14M; 12F) Identify structural GM and WM




OCD: ↑ symptom severity




HC: 16.5 ± 1.4 HC (14M; 12F) Clinical: YBOCS
[80] OCD: 22.0 ± 5.2 OCD (3M; 5F) Evaluated resting brain metabolism





improvement ~ ↑ changes in
bilateral dosal ACC and in
the right middle occipital
gyrus
HC: 21.5 ± 5.9 HC (8F) Clinical: YBOCS,
HDRS
Note. Sample: ADHD attention deficit hyperactivity disorder, ANX anxiety disorder, AUD alcohol use disorder, BPD bipolar disorder, BPD-I bipolar disorder I, BPD-O
bipolar disorder with obesity, BPD-L bipolar disorder with low alcohol use, BPD-H bipolar disorder with high alcohol use, BPD-N bipolar disorder without obesity,
BPD-NOS bipolar disorder not otherwise specified, BPD-R bipolar disorder remitters, BPD-NR bipolar disorder non remitters, BPD-RE bipolar disorder responders to
pharmacotherapy, BPD-NRE bipolar disorder non responders to pharmacotherapy, DD depressive disorder, CU cannabis user, GAD generalised anxiety disorder, gSP
generalised social phobia, HC healthy controls, HC-O healthy controls with obesity, HC-N healthy controls without obesity, MDD major depression disorder, MDDx
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with executive function deficits in these patients [53].
It is clear that the literature for anxiety disorders is
less consistent with regard to the pattern of cognitive
deficits and their relationship to anxiety and the sever-
ity of illness. The findings regarding GAD and cogni-
tion are unsurprisingly similar to the cognitive deficits
observed in depression, and provide support for a
shared underlying neurobiology for these disorders
[54].
Clinical trials utilizing neuropsychological function
as an outcome measure have demonstrated that ver-
bal memory improves following: (i) lamotrigine treat-
ment in bipolar patients [55]; and (ii) Transcranial
Magnetic Stimulation (TMS) treatment in depressed
patients [56]. Furthermore, the improved verbal mem-
ory performance was significantly associated with im-
provements in clinical symptoms of mania and
depression, in the former study, and with reductions
in hallmark symptoms of depression, in the latter.
This adds to the close and complex relationship ob-
served between cognition and mood disorders in
young people, and reiterates the need for future re-
search to closely examine the direction of these
relationships.
Neuroimaging
There were 62 studies (a total of 3069 participants;
55.5 % female) that utilised neuroimaging and across
these studies 62 % (1894/3069) were patients and 38 %
(1175/3069) were healthy controls. Among the patient
group 28 % (534/1894) had depression, 27 % (520/1894)
had bipolar, 15 % (288/1894) had anxiety, and 29 %
(552/1894) were classified as other (i.e. mixed psychiatric
samples, ADHD, alcohol use disorders, substance use
disorder).
Functional domains: social and economic participation,
physical health, suicide and self-harm & alcohol and
substance use
Results indicate that neuroimaging is a particularly use-
ful modality for investigating suicide and self-harm be-
haviours as well as alcohol and substance use. In
contrast, the utility of neuroimaging for investigating so-
cial and economic participation [57] and physical health
[58] outcomes is yet to be determined due to a lack of
studies exploring these relationships. Moreover, consist-
ent with the findings previously discussed (see 'Neuro-
psychology') linking poor cognitive flexibility and
decision making to suicidal behaviours, reduced Anterior
Cingulate Cortex (ACC) volume was associated with a
higher number of suicide attempts in patients with co-
morbid MDD and borderline personality disorder [59].
Furthermore, a study investigating ACC function using
fMRI demonstrated that individuals with a suicide at-
tempt history had increased dorsal ACC activity when
viewing angry faces, and reduced visual, sensory, pre-
frontal ACC activity to intense happy and neutral faces
compared to both healthy and psychiatric controls [60].
It is suggested that the ACC is an important area in-
volved in attentional control that regulates both cogni-
tive and emotional processes [61]. Structural and
functional abnormalities in this area may be indicative of
attentional control deficits that affect normal cognitive
and emotional processes that are associated with an in-
creased risk for suicidal behaviours in this population.
However further evidence for this theory is needed since
some fMRI studies could not distinguish between suicide
attempters and healthy controls using similar decision
making and cognitive flexibility tasks. Psychiatric con-
trols demonstrated increased activity in the ACC during
the go-no go task [62] and hippocampus during the
major depression disorder with borderline personality disorder, MHP mental health patients (mixed diagnosis sample), MT childhood maltreatment, OCD obsessive
compulsive disorder, PC psychiatric control (i.e. psychiatric diagnosis but no suicide attempt), PSD psychotic spectrum disorder, SA suicide attempters, ST stage of
illness; 1B, 2, & 3, SAD social anxiety disorder
Measures: AAS anxiety analogue scale, ACQ alcohol consumption questionnaire, ADIS anxiety disorders interview schedule, ASI addictions severity index, AUDIT
alcohol use disorder identification test, BDI beck depression inventory, BMI body mass index, PRS brief psychiatric rating scale, CALS child affect liability scale, CBCL
child behaviour checklist, CDI children’s depression inventory, CDRS children’s depression rating scale; R revised, CGAS children’s global assessment scale, CGI
clinical global impression scale, ChIPS children’s interview for psychiatric syndromes, CDDR customary drinking and drug use record, CGAS child global assessment
scale, C-CASA Columbia Classification Algorithm of Suicide Assessment, CSHF Colombia Suicide History Form, DTI diffuse tensor imaging, DUSI drug use screening
inventory, FH-RDC family history-research diagnostic criteria, fMRI functional magnetic resonance imaging, GAF global assessment of functioning, HAMA Hamilton
anxiety rating scale, HDRS Hamilton depression rating scale, K-SADS kiddie schedule for affective disorders and schizophrenia, LHAUD lifetime history of alcohol
use disorder, LIFE modified longitudinal interval follow-up examination, LOI-CV Leyton Obsessive Inventory-Child Version, LSAS Liebowitz social anxiety scale, MASC
multidimensional anxiety scale for children, MCQ meta cognition questionnaire, MFQ Mood frequencies questionnaire, MRS magnetic resonance spectroscopy, PET
positron emission tomography, PRS Pfeffer rating scale, OCDAS obsessive compulsive disorder analogue scale, RCADS the revised child anxiety and depression
scale, SAC substance abuse course-modified life II, SCARED screen for child anxiety related disorders, SCID structured clinical interview for DSM, SIQ suicide ideation
questionnaire, SIS suicide intent scale, SOFAS social and occupational functioning assessment scale, sMRI structural magnetic resonance imaging, STAI-C state- trait
anxiety inventory – child version, TLFB time-line followback, VBM voxel-based morphometry, Y-BOCS Yale–Brown obsessive-compulsive scale, YMRS young mania
rating scale, YSRS the youth self-report scale
Findings: ↑ = Increased, Improved or Higher, ↓ = Decreased, Reduced or Lower, ~ = ‘is associated with’, ACC anterior cingulate cortex, AD Axial diffusivity, ACG
Anterior Cingulate Gyrus, BA Broadman Area -24, BL baseline, CV cerebellar vermis, DmPFC dorsomedial prefrontal cortex, DWMH deep white matter
hyperintensities, FA fractional anisotropy, GABA gamma-aminobutyric acid, GM grey matter, GMV grey matter volumes, GSH glutathione, iFC intrinsic functional
connectivity, LFG left fusiform gyrus, MD mean diffusivity, MFG middle frontal gyus, MPFC medial prefrontal cortex, OFC orbitofrontal cortex, RD radial diffusivity,
PVH periventricular hyperintensities, PCG precentral Gyrus, PFC prefrontal cortex, TBV total brain volumes, TLV temporal lobe volume, VMPFC ventromedial
prefrontal cortex, WMH white matter hyperintensities, WMV White Matter Volumes
*indicates that the study features more than once in the data synthesis
Iorfino et al. BMC Psychiatry  (2016) 16:156 Page 18 of 38








[103] PD: 30.6 ± 6.1 PD (8M; 12F) Determine whether HPA








PD: ↑ cortisol secretion pre-






[102]* MDD (M): 12.8 ± 2.6,
MDD (F): 13.6 ± 1.9
MDD (22M; 33F) Investigate whether diurnal
changes in cortisol and DHEA
levels are associated with the





MDD: ↑ cortisol/DHEA ratios








(7 – 17.9 years)
MHP (62M; 40F) Investigate whether cortisol





MHP: ↑ cortisol secretion
during the social interaction






[105]* MDD: 25.19 ± 2.42 MDD (33M; 23F) Examine baseline
neuroendocrine predictors of






MDD: ↑ BL GH secretion
during first 4 hours of sleep
~ a suicide attempt during
FUP




[106] MDD: 25.19 ± 2.42 MDD (33M; 23F) Assess whether any
premorbid cortisol
abnormalities were associated







MDD: ↑ BL cortisol secretion
in the late evening hours ~




[107]* MDD: 16 ± 0.3 MDD (6M; 14F) Compare sleep EEG profiles





MDD: ↓ Delta sleep variable
~ ↑ suicidality (and





[108] CS: 17.04 ± 0.36 CS (57M; 173F) Examine whether individual
differences in the CAR serve




CS: ↑ cortisol after waking at




[118] HYP: 20.91 ± 3.72 HYP (8M; 23F) Assess circadian activity and
sleep in individuals at




HYP: ↑ variability in duration,
fragmentation and efficiency
of sleep, ↓ sleep duration and
later more variable be times.HC: 22.12 ± 2.83 HC (8M; 16F) Clinical: SCID,
HPS, HIQ, ISS
[120] MDD: 12 ± 1.9 MDD (2M; 4F) Explore the effects of
fluoxetine on sleep EEG
SWC: Sleep
EEG
MDD: ↑ stage 1 sleep,
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Table 5 Sleep-wake and circadian biology studies evaluating the five functional domains in young people (12-30 yrs) with a mood
and/or anxiety disorder (Continued)
[105]* MDD: 25.19 ± 2.42 MDD (33M; 23F) Examine baseline
neuroendocrine predictors of







and more steep GH secretion




[114] MDD: 17.04 ± 0.35 MDD (4M; 7F) Examine the associations
between MDD and anxiety




P-MDD & MDD/ANX: flatter
diurnal cortisol slopes






P-MDD: 17.13 ± 0.37 P-MDD
(11M; 45F)
P-ANX: 17.02 ± 0.38 P-ANX (6M; 2F)
[109] HR: 16.8 ± 1.7 HR (14M; 15F) Examine the cortisol increase
after awakening and basal
cortisol levels hypothesis that
high-risk offspring are more




HR: ↑ daytime cortisol in their
natural environment.
LR: 16.6 ± 2.1 LR (14M; 15F) Clinical: CDI,
CBCL, PANAS
[110] HR: 18.3 ± 2.6 HR (12M; 12F) Determine whether HR
individuals exhibit elevated
cortisol levels relative to LR




HR: ↑ afternoon cortisol levels
in their natural environment
LR: 18.0 ± 2.3 LR (11M; 11F) Clinical: BDI,
CDI, PSWQ,
CBCL, RLEQ
[102]* MDD (M): 12.8 ± 2.6 MDD (22M; 33F) Investigate whether diurnal
changes in cortisol and DHEA
levels are associated with the





MDD: ↑ cortisol/DHEA ratios
at BL ~ persistent major
depression at FUP




[113] Mild: 14.73 ± 2.30
Moderate: 15.69 ±
1.58
Mild (10M; 20F) Moderate
(7M; 9F)







↓ cortisol response regardless




Severe: 16.00 ± 2.00 Severe (6M; 19F)
[119] MDD: 23.94 ± 2.31 MDD (8M; 9F) Investigate the effect of





MDD: ↑ overnight dissipation




[107]* MDD: 16 ± 0.3 MDD (6M; 14F) Compare sleep EEG profiles





MDD: ↓ Delta sleep variable
~ ↑ depression severity.
HC: 15.6 ± 0.6 HC (7M; 6F)
Clinical:
HDRS






DD: ↓ sleep efficiency and
total time asleep, ↑ time
awake after sleep onset. ↑
pain intensity and depressive
symptoms predicted worse
sleep quality
HC: 14.83 ± 1.76 HC (17M; 43F) Clinical: K-
SADS, PDS,
CES-D, BPD
[111] MDD: 22.4 ± 1.5 MDD (9M; 17F) Examine the relationship
between longitudinal clinical




MDD: recurrent illness ~ ↑
plasma cortisol near sleep
onset at BL.
HC: 21.9 ± 1.7 HC (13M; 20F)
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Iowa Gambling Task (IGT) [34], compared to suicide
attempters who were comparable to healthy controls. It
may be that the ACC is associated with attentional con-
trol related to the emotive processing that has been
linked to suicide rather than the higher cognitive pro-
cesses investigated in these latter studies.
Alcohol and substance use appears to affect multiple
brain structures with most studies indicating that alco-
hol and substance use is associated with a pattern of re-
ductions in brain volume and impairments in brain
function. Cannabis use was investigated by two struc-
tural MRI (sMRI) studies where it was associated with
reduced total white matter volumes [63], and reduced
left fusiform gyrus grey mater volumes [64]. Whilst, the
only fMRI study investigating cannabis use reported that
lower amygdala reactivity was associated with higher
rates of cannabis use in MDD patients [65]. One study
[66] investigated alcohol use via sMRI and identified that
lower prefrontal cortex white matter and overall grey
matter volumes were associated with greater levels of
alcohol consumption. Collectively, these findings are
mostly consistent with the aforementioned neuropsycho-
logical studies (see 'Neuropsychology') and previous evi-
dence regarding the neurobiological effects of alcohol
Table 5 Sleep-wake and circadian biology studies evaluating the five functional domains in young people (12-30 yrs) with a mood
and/or anxiety disorder (Continued)
Clinical: K-
SADS
HC: high density REM and ↓
REM latency at BL ~ the
development of depression a
FUP





MDD: ↓ NUFC excretion
during remission
HC: 15.8 ± 1.9 HC (7M; 9F) Clinical: PRS,
HDRS, K-
SADS
[115] UPD: 21.8 ± 4.3 UPD (5M; 13F) Evaluate the potential of
circadian measures as early





BPD:↓ and later onset of
melatonin secretion





[116] HC: 24.8 ± 2.5 HC (8M; 12F) Investigate objectively the 24-
h sleep–wake cycle in adoles-




BPD: 62 % had delayed sleep
(during a depressive phase),
and later sleep offset





BPD: 23.2 ± 4.3 UPD: 30 % had delayed sleep
HC: 10 % had delayed sleep
[121] Stage 1a: 17.6 ± 4.0 Stage 1a (7M; 11F) Determine if disturbed sleep–
wake cycle patterns in young
people with emerging mental




Stage 1b & 2: ↑ delayed sleep
schedule, especially on
weeknights





Stage 2+: 22.4 ± 4.3 Stage 2+ (27M; 27F) Stage 1a & 2+: ↓ sleep
efficiency
HC: 24.4 ± 3.1 HC (11M; 12F)
Note. Sample: ANX anxiety disorder, BPD bipolar disorder, CS community sample, DD depressive disorder, HC healthy controls, HR high risk participants (offspring
of parents with bipolar disorder), HYP hypomanic participants, LR low risk participants (offspring of parents without a mental disorder), MDD-ANX comorbid Major
depressive disorder and anxiety disorder, MDD major depression disorder, MHP mental health patients (mixed diagnosis sample), P-MDD past major depressive
disorder, P-ANX past anxiety disorder, PD panic disorder
Measures: ACTH adrenocorticotropic hormone, BDI beck depression inventory, BPD body pain diagram, CBCL child behaviour checklist, CDI children’s depression
inventory, CDRS children’s depression rating scale, CECA childhood experience of case and abuse contextual semi-structured interview and rating system, CES-D
Center for Epidemiologic Studies Depression, CRH corticotropin-releasing hormone, DHEA dehydroepiandrosterone, DLMO dim light melatonin onset, DSM-IV
diagnostic and statistical manual of mental disorders IV, EEG electroencephalography, GH growth hormone, HDRS Hamilton depression rating scale, HPS hypo-
manic personality scale, HIQ hypomanic interpretations questionnaire, ISS internal state scale, K-SADS schedule for affective disorders and schizophrenia for school
age children, LSI life stress interview, MASQ mood and anxiety symptom questionnaire, NUFC nocturnal urinary free cortisol, PANAS positive and negative affect
scale, PDS pubertal developmental scale, PRS Pfeffer rating scale, PSWQ Penn state worry questionnaire, QIDS quick inventory of depressive symptomatology,
RLEQ recent life events questionnaire, SASC social anxiety scale for children, SCID structured clinical interview for DSM, SDS Sheehan disability scale, SWC sleep-
wake and circadian biology, WSAS work and social adjustment scale
Findings: ↑ = Increased, Improved or Higher, ↓ = Decreased, Reduced or Lower, ~ = ‘is associated with’, BL baseline, FUP follow-up, NUFC nocturnal urinary free
cortisol, REM rapid eye movement, SWA slow wave activity
*indicates that the study features more than once in the data synthesis
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Nα: MMN BPD & PSD: ↑ BL MMN ~ ↑ social and






[191]* MDD: 17.1 ± 0.6 MDD (8F) Investigate the effect of
nicotine on resting EEG
activity and affect.
Nα: EEG MDD: ↓ rPR theta & ↓ smoking
withdrawal, craving and physical





[122] SA: 29.5 ± 13.3, HC:
34 ± 13.3
SA (24M; 16F) Investigate the trait






SA: ↓ CNV and whole blood 5-HT ~
multiple episodes of self-harm.
HC (13M; 14F) Functional: HLS,
MADRS, SIS





SA: ↑ posterior alpha asymmetry ~
suicidal intent (not depression
severity)
HC: 14 (12 – 17yrs) HC (22F) Functional: HASS,
SIS
[124] rMDD + CSA:
31.60 ± 10.98
rMDD + CSA (15F) Examine the association
between CSA, MDD and
maladaptive behaviour.
Nα: EEG rMDD + CSA: ↑ subgenual ACC
activation during reward based
decision making, ↓ reaction time
during incentive-based trials ~ ↑ fre-
quency of self harm/suicidal
behaviours.
rMDD: 24.81 ± 3.94 rMDD: (16F) Functional: YRBS
(adult version)
HC: 30.44 ± 10.78 HC (18F)
Alcohol and
substance use
[192] BPD-L: 21.8 ± 3.9 BPD-L (5M; 11F) Investigate the effects of
alcohol use on MMN in BP.
Nα: MMN BPD-H: ↓ temporal MMN
BPD-H: 22.6 ± 3.4 BPD-H (9M; 17F) Functional: AUDIT
HC-L: 22.4 ± 2.6 HC-L (6M; 14F)
HC-H: 23.4 ± 3.2 HC-H (6M; 8F)




Nα: Startle, ERP AD: ↑ facilitation, ↓ inhibition of the
N4S component by pre pulse
stimuli.BD: 24.6 ± 5.76 BD (23M; 18F) Functional:
SSAGA, FHAM
AFF: 22.9 ± 3.94 AFF (32M; 65F)
DD: 23.5 ± 3.17 DD (51M; 61F)
Clinical
syndrome






ANX: ↓ in multiple muscle ASR ~ ↓ in
anxiety symptoms.
HC: 12.0 ± 2.5 HC (10M; 15F) Clinical: ADIS-C/P,
SCAS
ANX: ↑ multiple muscle ASR
predicted CBT treatment response
[133] OCD: 13.9 ± 2.4 OCD (18M; 22F) Assess ERN as a biomarker
for OCD
Nα: ERN OCD & SIB: ↑ ERN at Cz
(independent of symptom severity,
current diagnostic status and
treatment effects).
SIB: 13.9 ± 2.4 SIB (13M; 6F) Clinical: Y-BOCS,
CBCL, MASC, CDI
HC: 13.8 ± 2.3 HC (20M; 20F)
[134] ANX: 11.8 ± 2.3 ANX (3M; 10F) Demonstrate ERN
amplitude is increased in
young anxiety patients.
Nα: ERN ANX & OCD: ↑ ERN at Cz
(independent of symptom severity,
current diagnostic status and
treatment effects).
OCD: 12.7 ± 2.2 OCD (8M; 18F) Clinical: Y-BOCS,
CBCL, MASC, CDI
HC: 12.4 ± 2.2 HC (14M; 13F)




Nα: TMS NoRES: ↑ deficits in pre-treatment
LICI
NoRES: 13.1 ± 1.6 NoRES (5M; 3F) Clinical: CDRS-R,
QIDS, CGI-severity
scale
[195] HC: 25.54 ± 3.41 HC (28M; 16F) Investigate the intensity
evaluation of social stimuli
in depression
Nα:
ERP (N170, P1, P2)
MDD: ↑ intensity scores for sad faces
compared with HC, ↑ reaction times
for all faces and ↑ P1 & P2
amplitude for sad facesDEP: 25.96 ± 4.58 DEP (9M; 15F) Clinical: SCID, BDI,
HDRS, BAI
MDD: 26.58 ± 4.16 MDD (10M; 14F) DEP: ↓ scores for happy and neutral
faces, ↑ reactions times and ↑ P1 &
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Table 6 Neurophysiological studies evaluating the five functional domains in young people (12-30 yrs) with a mood and/or anxiety
disorder (Continued)
P2 amplitude for happy faces
compared to sad faces.
[196] HC: 27.7 ± 7.0 HC (14M; 12F) Assess brain function
impairments in bipolar
patients.
Nα: Resting EEG BPD: ↑ power in all wave bands.
Marked increases in right temporal
theta and left occipital beta.BPD: 30.7 ± 6.1 BPD (10M; 19F) Clinical: BDI
[135] OCD: 13.3 ± 2.8, OCD (13M; 5F) Examine ERN in paediatric
patients with OCD
Nα: ERN OCD: ↑ ERN pre-treatment and after
treatment. No relationship with
symptom severity or changes in
symptom severity
HC: 11.9 ± 2.6 HC (8M; 10F) Clinical : Y-BOCS
[197] HC: 17 ± 1.6 HC (43F) Evaluate the effects of
depression and a family
history of alcohol or
substance dependence on
P300.
Nα: ERP (P300) DD: ↓ P300 amplitude. No effect of
family history of alcohol or drug
dependence.HC-FHA: 16.5 ± 1.3 HC-FHA (31F) Clinical: SSAGA,
MAST, PANAS
HC-FHD: 16.1 ± 1.5 HC-FHD (27F)
DEP: 17.2 ± 1.4 DD (12F)
DEP-FHA: 17.3 ± 1.5 DD-FHA (9F)
DEP-FHD: 16.3 ± 1.3 DD-FHD (8F)
[191]* MDD: 17.1 ± 0.6 MDD (8F) Investigate the effect of
acute nicotine
administration on resting
EEG activity and affect
Nα: EEG MDD: Nicotine ↓ theta amplitude in
right parietal region. No associations
with mood.Clinical: BDI,
HONC, PANAS
[129] MDD: 30.4 ± 11.8 MDD (28M; 23F) Assess the utility of baseline
LDAEP predicting response
to antidepressants.
Nα: LDAEP MDD: steep N1 sLORETA-LDAEP at
BL ~ treatment response. ↑ P2




[167]* OCD: 27 ± 9.8 OCD (15M; 16F) Characterize the cognitive
functions of the patients
with OCD by utilizing ERPs
and neuropsychological
tests
Nα: ERP (P300) OCD: ↓ P300 duration. ↓ stroop
duration ~ ↑ P300 amplitude in
occipital, parietal and temporal
anterior regions.
HC: 27.4 ± 9.1 HC (14M; 16F) Clinical: HDRS
[52]* OCD: 24.06 ± 5 OCD (21M; 9F) Assess the relationship
between cognitive
dysfunction, clinical status
and severity in OCD.
Nα: ERP (N100,
P200, N200, P300)
OCD: ↑ P200 amplitude, unrelated to
neither severity nor chronicity of
illness. ↓ N200 amplitude (worsens
with ↑ severity). ↓ N100 and P200
~ ↑ chronicity
HC: Matched HC (21M; 9F)
Clinical: YBOCS
[136] OCD-U: 25 ± 8.0 OCD-U (9M; 10F) Examine the effects of
chronic medication on
error responses in OCD.
Nα: ERN OCD: ↑ ERN, irrespective of
medication use.
OCD-M: 30.8 ± 9.5 OCD-M (9M; 10F) Clinical: HDRS,
HAMA, YBOCS
PC-M: 31.7 ± 10.6 PC-M (8M; 11F) HC & PC: ↑ anxiety and depression
~ ↑ ERN amplitude
HC: 25.3 ± 7.5 HC (11M; 10F)
[127] DEP: 20.9 ± 0.55 DEP (515) Examine whether recurrent
major depression is associated
with abnormal startle
Nα: ASR DEP: ↑ ASR was associated with
multiple (more than 1) depressive
episode.Clinical: SCID
Note. Sample : AFF affective disorder (not specified), AD alcohol dependence, ANX anxiety disorder, BD behavioural disorder, BPD bipolar disorder, BPD-L bipolar disorder
with low alcohol use, BPD-H bipolar disorder with high alcohol use, DD depressive disorder, DD-FHA depressive disorder with family history of alcohol dependence, DD-FHD
depressive disorder with family history of drug dependence, DrDep drug dependence, HC healthy controls, HC-FHA healthy control with family history of alcohol depend-
ence, HC-FHD healthy control with family history of drug dependence, HC-L health control with low alcohol use, HC-H healthy control with high alcohol use, MDD major de-
pression disorder, MHP mental health patients (mixed diagnosis sample), NoRES treatment non responders, OCD obsessive compulsive disorder, OCD-M obsessive
compulsive disorder patient medicated, OCD-U obsessive compulsive disorder patients unmedicated, PC-M psychiatric control patient medicated, PSD psychotic spectrum
disorder, RES treatment responders, rMDD remitted major depression disorder, rMDD+CSA remitted major depression disorder with childhood sexual abuse history, SA sui-
cide attempters, SIB suicide ideation behaviour
Measures : ADIS-C/P anxiety disorders interview schedule for children, ASR auditory startle reflex, AUDIT Alcohol Use Disorder Identification Test, BAI beck anxiety
inventory, BDI beck depression inventory, CBCL child behaviour checklist, CDI children’s depression inventory, CDRS children’s depression rating scale, CGI clinical
global impression scale, EEG electroencephalography, ERP event related potential, ERN event related negativity, FHAM family history assessment module, HAMA
Hamilton anxiety rating scale, HASS Harkavy Asnis suicide scale, HDRS Hamilton depression rating scale, HLS beck hopelessness scale, HONC hooked on nicotine check-
list, LDAEP loudness dependant auditory evoked potential, MASC multidimensional anxiety scale for children, MADRS Montgomery-Asberg depression rating scale,
MMN mismatch negativity, MAST Michigan Alco- holism Screening Test, PANAS positive and negative affect scale, QIDS quick inventory of depressive symptomatology,
SCID structured clinical interview for DSM, SCAS Spence children’s anxiety scale, SIS suicide intent scale, SOFAS social and occupational functioning assessment scale,
SSAGA semi-structured assessment for the genetics of alcoholism, TMS transcranial magnetic stimulation, WHO-DAS-II World Health Organisation Disability Assessment Scale
II, Y-BOCS, Yale–Brown obsessive-compulsive scale, YRBS youth risk behaviour survey
Findings : ↑ = Increased, Improved or Higher, ↓ = Decreased, Reduced or Lower, ~ = ‘is associated with’, 5-HT serotonin, BL baseline, CBT cognitive behaviour ther-
apy, CNV contingent negative variation, FUP follow-up, N4S late wave frontal ERP component responses, rPR right Parietal Region, RT reaction time
* indicates that the study features more than once in the data synthesis
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and substance misuse on the structure and function of
frontal and temporal brain regions [67].
Functional domain: clinical syndrome
From the fifty neuroimaging studies investigating clinical
syndrome, multiple regions of interest have been studied
using a variety of imaging methods.
Structural magnetic resonance imaging (sMRI) In de-
pressive disorders the majority of studies examining
brain structure have focused on frontal and limbic re-
gions with mixed findings; although some promising
patterns emerge when the severity and/or clinical course
of specific disorders are considered. Reduced ACC vol-
umes [68, 69], and increased ACC thickness [70], have
been identified in MDD patients compared to healthy
controls. Whilst, no significant association with clinical
severity or symptoms was found in these studies, re-
duced ACC volume was associated with higher border-
line personality disorder symptom severity but not
depression, in patients diagnosed with comorbid MDD
and borderline personality disorder [59]. Some further
lines of inquiry provide greater detail about how the se-
verity of the clinical syndrome may influence or be influ-
enced by particular brain structures. Decreased grey
matter volume in frontal brain regions were evident in
patients with a discrete or persistent affective illness
compared to those with attenuated syndromes and
healthy controls [71], and MDD patients who experi-
enced more than three untreated depressive episodes
had reduced subcallosal gyrus volumes, an ACC sub-
division [72]. Collectively, these studies reiterate the
relationship between reductions in the ACC and depres-
sion, and suggest that greater reductions in the ACC
may be associated with more severe illness.
Compared to healthy controls, MDD patients had
lower amygdala volumes, and no association with clin-
ical severity or illness duration [73], however MDD pa-
tients near the onset of their illness had increased
amygdala-hippocampal volume ratios that were associ-
ated with higher severity of anxiety, but not depression
severity [74]. This is consistent with evidence indicating
that larger amygdala volumes in GAD patients are asso-
ciated with greater symptom severity [75]. This suggests
that common forms of depression and anxiety may share
similar biological processes and genetic liability [76, 77],
yet differ in their phenotypic expression. Although dis-
tinct pathophysiology may underlie the development of
SAD, since lower amygdala grey matter density was as-
sociated with greater disease duration and earlier age of
onset in this group [78].
Changes to areas of the brain following a course of treat-
ment can provide valuable insight into the success of
treatment and how this may have influenced the course of
illness. Compared to healthy controls, treatment naïve pa-
tients with OCD had larger thalamic volumes, which nor-
malised following paroxetine treatment. These reductions
were also associated with a decrease in OCD symptoms.
While, CBT treatment for OCD was not associated with
change in thalamic volumes [79], greater symptom im-
provement following CBT was associated with a normalised
metabolism in the ACC [80], and with increased prefrontal
grey matter volumes [81]. These studies are consistent with
the association between the lower symptom severity and
greater prefrontal grey matter volumes [82]. Higher com-
pulsive symptom severity was associated with reduced pitu-
itary gland volume in OCD patients in males, compared to
healthy controls [83], and larger corpus callosum area [84].
Collectively these OCD studies seem to indicate that
pharmacological treatment for OCD may be particularly
useful for targeting deficits in thalamus structure and func-
tion, whilst CBT may be better for targeting clinical features
associated with prefrontal structures.
Functional magnetic resonance imaging (fMRI) Stud-
ies investigating brain function using fMRI have also
predominantly focused on frontal and limbic regions.
Clinical improvement following lamotrigine treatment
for bipolar disorder [85], and SSRI treatment for gener-
alised social phobia [86], were associated with reduc-
tions in amygdala activation whilst viewing negative
valanced emotional pictures. Similarly, higher activa-
tion of the amygdala to emotionally fearful faces com-
pared to happy faces was associated with treatment
response to CBT or medication in anxiety patients
[87]. Bipolar disorder pharmacotherapy treatment re-
sponders compared to non-responders had greater
amygdala functional connectivity within the frontolim-
bic network, and higher amygdala functional connect-
ivity within this network after treatment was
associated with greater improvements in mania symp-
toms [88]. These studies consistently demonstrate a re-
lationship between higher amygdala activity and
patterns of treatment response for both bipolar and
anxiety disorders. This may be indicative of a shared
neurobiological vulnerability for heightened amygdala
reactivity associated with stress and the emergence of
particular affective disorders [89].
Diffusion Tensor Imaging (DTI) The evidence from
these DTI studies collectively indicate that poorer
white matter integrity is associated with affective dis-
orders that may be an early marker of disorder. A
diagnosis of a depressive disorder, compared to
healthy controls was associated with lower fractional
anisotropy, a measure indicating poorer white matter
integrity, and higher mean and radial diffusivity in the
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Table 7 Metabolic studies evaluating the five functional domains in young people (12-30 yrs) with a mood and/or anxiety disorder
Outcome
measure
Study Age (mean ± SD) Sample (N) Aims Key measures Key findings
Social and
participation
[140]* MHP: 28.74 ± 10.38 MHP (38M; 28F) Identify changes in the
rates of obesity in
never-treated patients
with mood disorder
over 4 years of follow-
up.
Metabolic: BMI MHP: ↑ BMI ~ ↑ social and
economic participation
(40 MDD, 26 BPD) Functional: GAF
Physical
health
[198] FH+: 18.9 ± 1.0 FH+ (32M, 53F) Determine whether





glucose, lipids and high-
sensitivity CRP. BP, arterial
stiffness and waking cor-
tisol concentration.
FH+: ↑ peripheral and central
BP, arterial stiffness and ↓
insulin sensitivityHC: 19.1 ± 0.1 HC (27M; 42F)
Suicide and
self-harm






SUC: ↑ cholesterol ~ current
suicide behaviour (within the
SUC group, ↑ serum
cholesterol ~ ↓ severity of SUC,
but not ~ symptom severity)
PC: 16.22 ± 1.95 PC (58M; 47F) Functional: SPI
PD: 25.3 ± 3.3 PD (37M; 35F) Elucidate the
relationships between
alexithymia, suicide




PD: ↓ HDL-C and ↑ VLDL-C ~
higher suicide ideation
Functional: SSI





SA: ↓ cholesterol levels ~
attempted suicide history
PC: 15.19 ± 1.68 PC (15M; 39F) Functional: hospital
records
[199] SA: 16.8 SEM = .74 SA (3M; 6F) Investigate platelet PBR
density in suicidal teens
Metabolic: blood serum
samples
SA: ↓ platelet PBR density
PC: 16.5 SEM = .5 PC (7M; 3F) Functional: hospital
records, SPI, SRS







SA: ↓ plasma 5-HT level ~ ↑
suicidality. (5-HT did not dis-
criminate between the psychi-
atric diagnostic categories)PC: 16.29 1.81 PC (19M; 11F) Functional: hospital
records, SPI
ER: 16.91 2.47 ER (13M; 38F)








Metabolic: BMI BPD: SUD ~ 2.8 fold increased
prevalence of BPD-OB.
BPD-NO: 13.3 ± 3.0 BPD-NO (108M; 95F) Functional: K-SADS-P
Clinical
syndrome
[162] MDD: 24.1 ± 3.2 MDD (45M; 44F) Examine the association
between MDD in
childhood and BMI in
adulthood
Metabolic: BMI MDD: ↑ BMI at FUP (in
adulthood)
HC: 22.2 ± 2.9 HC (43M; 45F) Clinical: KSADS,
[140]* MHP: 28.74 ± 10.38 MHP (38M; 28F) Identify changes in the
rates of obesity in never-
treated patients with
mood disorder over 4
years of follow-up.
Metabolic: BMI MHP: clinical improvement ~ ↑
BMI
(40 MDD, 26 BPD) Clinical: HAMD
Note. Sample : BPD bipolar disorder, BPD-O bipolar disorder with obesity, BPD-NO bipolar disorder without obesity, ER emergency room patients admitted for sui-
cide attempt, HC healthy controls, FH+ family history of depression, MDD major depression disorder, MHP mental health patients (mixed diagnosis sample), PC
psychiatric control (i.e. psychiatric diagnosis but no suicide attempt), PD panic disorder, SA suicide attempters, SUC suicidal tendencies (either ideation, threat
or attempt)
Measures : BMI body mass index, BP blood pressure, CRP C-reactive protein, GAF global assessment of functioning, HDRS Hamilton depression rating scale, K-
SADS schedule for affective disorders and schizophrenia for school age children, SPI suicide potential interview, SRS suicide risk scale, SSI scale of suicide ideation
Findings : ↑ = Increased, Improved or Higher, ↓ = Decreased, Reduced or Lower, ~ = ‘is associated with’, 5-HT serotonin, FUP follow-up, PBR peripheral-type
benzodiazepine receptors
* indicates that the study features more than once in the data synthesis
Iorfino et al. BMC Psychiatry  (2016) 16:156 Page 25 of 38
corpus callosum, whilst higher fractional anisotropy
and axial diffusivity and lower radial diffusivity in the
uncinated fasciculus [90]. Lower fractional anisotropy
in the ACC [91], and genu, body and splenium of the
corpus callosum as well as the superior and anterior
corona radiata [92] is evident in bipolar disorder
compared to healthy controls. For those who experi-
enced maltreatment during childhood, compared to
healthy controls, MDD at follow up was associated
with lower fractional anisotropy in the superior longi-
tudinal fasciculi and the right cingulum-hippocampal
projection, whilst substance use disorder at follow up
was associated with lower fractional anisotropy in the
right cingulum-hippocampal projection [93]. Greater
obsession symptom severity in OCD patients was
associated with higher fractional anisotropy in the
splenium [94]. Lower white matter integrity in the
genu of the corpus callosum, anterior thalamic radi-
ation, anterior cingulum and sagittal stratum was as-
sociated with higher depression severity in MDD
patients [95]. Having a discrete or persistent psychi-
atric illness was associated with lower fractional an-
isotropy in the left anterior corona radiata compared
to healthy controls, whilst a similar pattern of lower
fractional anisotropy within this region was associated
with attenuated syndromes of psychiatric illness [96].
Magnetic Resonance Spectroscopy (MRS) In terms of
MRS studies, the major metabolites that were investigated
include N-acetyl aspartate - a measure of neuronal integ-
rity; choline - involved in cell membrane production, lac-
tate - marks glycolysis has been initiated in an oxygen
deficient environment; creatine - indicates metabolism of
brain energy; glutamate/glutamine -an excitatory neuro-
transmitter involved in neural activation; and GABA - an
inhibitory neurotransmitter involved in reducing neuronal
excitability [97]. Lower total choline in the left striatum
was associated with OCD and remained consistent over
the course of illness [98]. Compared to healthy controls,
bipolar disorder was associated with a higher lactate to N-
acetyl aspartate and lactate to creatine ratios [99], and
higher N-acetyl aspartate in the ACC and higher N-acetyl
aspartate, choline and creatine in the ventral lateral pre-
frontal cortex [100]. Moreover, bipolar disorder re-
sponders had lower left ventral lateral prefrontal cortex
glutamate/glutamine [101]. For both MDD patients and
healthy controls, higher ACC GABA was associated with
lower anhedonia scores, and lower ACC GABA was asso-
ciated with MDD [68].
Sleep-wake and circadian biology
This section entails studies that have utilised either
sleep physiology (e.g. sleep EEG) and/or sleep-wake
monitoring (e.g. actigraphy) or indicators (e.g. cortisol
secretion) to determine sleep-wake and circadian
function. There were 23 studies (a total of 1609 par-
ticipants; 59.3 % female) that utilised sleep-wake and
circadian biology and across these studies 84 %
(1352/1609) were patients and 16 % (257/1609) were
healthy controls. Among the patient group 55 %
(747/1352) had depression, 3 % (45/1352) had bipolar,
5 % (69/1352) had anxiety, and 36 % (491/1352) were
classified as other.
Functional domains: social and economic participation,
physical health, suicide and self-harm & alcohol and
substance use
Sleep-wake and circadian biology appears to be useful
for characterising two functional domains in young
people, namely social and economic participation, and
suicide and self-harm behaviours. Three sleep-wake and
circadian studies investigated the relationship between
salivary cortisol secretion and social and economic par-
ticipation. Two of these studies [102, 103] were longitu-
dinal investigations that identified that increased salivary
cortisol at baseline [102], and before alprazolam treat-
ment for patients with panic disorder [103] predicted
poorer social and economic participation at follow up.
Such results suggest that increased HPA activity, indexed
by a greater salivary cortisol response, may be indicative
of HPA axis deregulation with prognostic significance
and not simply a cross sectional marker of stress and ac-
tive illness. Similarly, the one cross-sectional study [104]
found that increased cortisol secretion during a social
interaction task was associated with poorer social func-
tioning. Alone, this study would seem to demonstrate
that increased cortisol secretion is a state marker of so-
cial stress, however in light of the previous longitudinal
studies, it is possible that heightened HPA activity is in-
dicative of a persistent dysregulated stress response to
social specific cues. Notably, all three of these studies
were published over 15 years ago, suggesting the need
for new evidence to explore the relationships identified
by the longitudinal studies.
Three sleep-wake and circadian studies were longitu-
dinal and identified a relationship with suicide outcomes
in MDD patients. At baseline, higher growth hormone
secretion during the first 4 h of sleep [105], and higher
cortisol secretion in the late hours of sleep [106] were
both associated with the emergence of a suicide attempt
at follow-up. The final study [107] identified that re-
duced delta sleep activity was associated with higher
levels of suicidality as well as depression severity.
Similarly, to the social and economic participation stud-
ies, these biological substrates also point to HPA dysreg-
ulation as a predictor of later suicide attempts in MDD
patient groups.
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Functional domain: clinical syndrome
Of the eighteen sleep-wake and circadian biology studies,
nine studies investigated clinical syndrome utilising corti-
sol responses. Whilst, the timing of cortisol secretion var-
ied between studies, the findings consistently indicate that
increased cortisol response is associated with the develop-
ment [108–110] and persistence [102, 111] of MDD,
whilst remission [112] is associated with reductions in cor-
tisol measures. The heterogeneity of depression becomes
clearer with evidence of moderate-to-severe depression
being associated with significant blunting of the cortisol
response compared to those with mild depression, who
had increased cortisol secretion during a stress task [113].
These results suggest that the neurobiological systems me-
diating the stress response are functioning very differently,
and may indicate distinct pathophysiological drivers of de-
pression for these two groups. Specifically, genetically me-
diated depression associated with increased severity and
chronic stress leading to a desensitization of glucocortic-
oid receptors versus mild to moderate depression arising
from predominately environment risk factors with typical
HPA abnormalities [113]. This pattern of findings appears
to differ for comorbid MDD and anxiety, which was asso-
ciated with flatter diurnal cortisol slopes (daytime cortisol
activity) [114], suggesting that the presence of anxiety in-
fluences cortisol function in a way that contrasts to de-
pression alone.
Studies that investigated the relationship between the
sleep-wake cycle and clinical syndrome reported quite
consistent findings. When compared to unipolar depres-
sion, bipolar disorder is associated with delayed onset
and lower levels of melatonin secretion [115], as well as
increased rates of delayed sleep [116]. Similarly, poor
sleep efficiency and lower sleep duration was reported in
both unipolar depression [117] and hypomanic individ-
uals [118] compared to healthy controls. Increased de-
pression severity was associated with reduced delta sleep
[107], while higher overnight dissipation of slow wave
sleep predicted a reduction in depressive symptoms
[119]. Similarly, greater high density REM and lower
REM latency at baseline was associated with the devel-
opment of depression at follow in healthy controls [111],
whilst another found that greater high density REM was
associated with fluoxetine treatment in patients with
MDD [120]. Whilst these sleep-wake cycle deficits are
evident in those with a full threshold disorders (both
unipolar and bipolar disorder), increased rates of delayed
sleep are also evident in individuals with either a discrete
disorder or an attenuated syndrome compared to indi-
viduals with mild symptoms and healthy controls [121].
This indicates that a similar pattern of sleep-wake deficit
are also evident in those with subthreshold disorders
and highlight that such deficits can be identified earlier
in the course of illness.
Neurophysiology
There were 21 studies (a total of 2034 participants;
69.6 % female) that utilised neurophysiology and across
these studies 74 % (1510/2034) were patients and 26 %
(524/2034) were healthy controls. Among the patient
group 56 % (851/1510) had depression, 9 % (130/1510)
had bipolar, 21 % (313/1510) had anxiety, and 14 %
(216/2034) were classified as other.
Functional domains: social and economic participation,
physical health, suicide and self-harm & alcohol and
substance use
Evidence from the included studies indicated that neuro-
physiology may be particularly useful for characterising
suicide and self-harm behaviours, and alcohol and sub-
stance use. Three separate neurophysiological studies
found an association with specific types of suicide and
self-harm behaviours. Specifically, lower contingent
negative variation was associated with multiple episodes
of deliberate self-harm [122], increased posterior EEG
alpha asymmetry was associated with suicidal intent and
the lethality of suicide attempt, but not depression sever-
ity, in suicide attempters [123], and slower reaction
times during incentive based decision making tasks was
associated with increased frequency for suicide and self-
harm behaviours in remitted MDD patients [124]. To-
gether these findings link abnormal brain functions im-
plicated in decision making processes to different types
of self-harm and suicidal behaviours [125, 126].
Functional domain: clinical syndrome
With regard to the fifteen neurophysiology studies, a
number of these examined the relationship between
treatment response and neurophysiological markers
using a number of methods. Firstly, increased startle re-
sponse was associated with multiple episodes of depres-
sion in depressed individuals [127]. Increased startle
response was also associated with the presence of an
anxiety disorder compared to healthy controls [128]. In
this study, a reduction in acoustic startle response was
associated with a reduction in anxiety symptoms follow-
ing CBT, and a higher startle response at baseline pre-
dicted treatment response. Similarly, steep N1 of the
Loudness Dependency of Auditory Evoked Potentials
(LDAEP) at baseline and higher P2 LDAEP at week 1
predicted anti-depressant treatment response in patients
with MDD [129]. These findings are consistent with the
phenomenon described in this paper (see 'Neuroimag-
ing') that link maladaptive processes associated with in-
creased threat processing measured at a neural,
psychological and behavioural level [130]. These findings
implicate the amygdala as the predominate brain region
involved in threat processing, however it functions as
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part of a wider brain circuit involving the dorsal medial
prefrontal (anterior cingulate) cortex [131, 132].
Four studies utilised Event Related Negativity (ERN) to
characterise the clinical syndrome of OCD patient
groups. All four studies found that increased ERN was
associated with OCD compared to healthy controls
[133–136], however none identified a relationship with
symptoms severity, treatment status or medication use.
Conversely the N100 ERP had an inverse relationship
with symptom severity, whilst both the N100 and P200
had an inverse relationship with illness chronicity [52].
These studies indicate that ERN may be a trait measure
associated with OCD independent of symptoms severity,
diagnosis and/or treatment effects, while the ERP N100
and P200 may be measures sensitive to illness specific
factors (e.g. chronicity).
Metabolic
There were 10 studies (a total of 1,385 participants; 43 %
female) that utilised metabolic measures and across
these studies 80 % (1133/1385) were patients and 18 %
(252/1385) were healthy controls. Among the patient
group 22 % (254/1133) had depression, 35 % (400/1133)
had bipolar, 6 % (72/1133) had anxiety, and 36 % (407/
1133) were classified as other.
Functional domains: social and economic participation,
physical health, suicide and self-harm & alcohol and
substance use
Three metabolic studies investigated the relationship be-
tween suicide and self-harm behaviours and cholesterol.
Lower total cholesterol levels were associated with a sui-
cide attempt history [137], and increased severity of sui-
cidal behaviour (e.g. ideations, gestures) among those
who were currently suicidal [138], while lower high
density lipid cholesterol was associated with higher sui-
cide ideation [139]. Together these findings seem to in-
dicate that lower cholesterol is associated with the
spectrum of suicidal behaviours, particularly in males.
However, this is an area of contention since higher total
cholesterol was associated with current suicidal behav-
iour versus those not currently suicidal. These findings
highlight the complex association between suicidal be-
haviours and cholesterol, and indicate that its usefulness
a biological marker needs further clarification.
Two studies examined the correlates of the risk of
obesity, indexed by BMI, among young people with
mood disorders. Substance use was associated with an
2.8 fold increased risk of overweight/obesity among bi-
polar patients and increased BMI was associated with
better social and economic participation over a 4-year
longitudinal study in mood disorder patients (unipolar
and bipolar) [140]. The latter study also reported an
increase in the prevalence rates for overweight/obesity,
consistent with the finding of the former study. There
are a number of illness related factors that could explain
this relationship which include a return of normal appe-
tite, medication use, self-modulation of mood by over-
eating [141] as well as biological factors implicated in
mood, and metabolic function and weight maintenance,
such as leptin [142] and neurotransmitter abnormalities
[143].
Functional domain: clinical syndrome
See Table 7 for individual results.
Discussion
As expected, there is a predominate focus in the litera-
ture on clinical syndrome in young patients compared to
the other four functional domains (i.e. social and eco-
nomic participation, physical health, suicide and self-
harm behaviours and alcohol and substance use). Whilst
the neurobiology of these clinical syndromes have been
extensively reviewed previously [131, 144], we provide
an overview of these findings. Typically biomarkers of
the clinical syndrome alone do not readily provide a
complete understanding of disability and the risk factors
that put young people at greater risk for a worse illness
trajectory [3]. This review demonstrates the use of these
biomarkers to investigate multiple functional domains in
addition to the clinical syndrome. It is clear that the na-
ture of the relationship between the underlying neuro-
biology and functional domains is an issue that needs to
be resolved in this area. However, overall this review ex-
hibits the usefulness of neurobiological parameters to as-
sess these additional functional domains and identify
treatment targets, in addition to the traditional focus on
clinical syndrome, to optimise interventions and im-
prove illness trajectories.
Implications for personalised psychiatry
The search for gold standard screening or diagnostic
tests has ultimately been unsuccessful, however the in-
creasing emphasis on personalised (or ‘stratified’) psych-
iatry has the potential to make significant advances in
terms of clinical validity and applicability [145]. Whilst,
conventional diagnostic methods remain entirely rele-
vant, the addition of the neurobiological markers that in-
dicate prognosis or potential treatment targets are
essential for advancing personalised psychiatry. Utilising
individual characteristics to guide treatment decisions is
key to personalised medicine and providing person-
centred care. This review exhibits the utility of the
RDoC approach to investigate individual characteristics
that extend to functional domains that contribute to on-
going disability and poorer outcomes. By collating the
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available evidence, this systematic review provides a
basis for future investigations to further evaluate the
clinical utility of specific neurobiological markers and
their relationship with these functional domains (Fig. 2).
Social and economic participation
Our findings suggest that those with more severe im-
pairments in memory and executive functioning are at
the greatest risk for diminished participation in educa-
tion, employment and social settings. The use of
cognitive tests that characterise memory and executive
functions of young people with emerging illnesses may
be particularly useful for identifying individuals who are
at risk of poor social and economic participation out-
comes. Unlike diagnosis, neuropsychological function in-
dependently predicts social and economic participation
outcomes in young people with emerging mood
disorders [146]. The evidence suggests that neuropsych-
ology, specifically memory and executive function, may
mediate these outcomes in young people. Therefore,
Fig. 2 The potential neurobiological targets associated with mental illness trajectory organised by functional domain. This is a model illustrating
the potential neurobiological targets for each functional domain identified by this systematic review. At the centre is ‘mental illness trajectory’
that is a term employed here to encompass all the characteristic features of illness, and its associated short term and long term outcomes.
Surrounding this are the five functional domains investigated by this review to illustrate how a young person’s mental illness trajectory is made
up of and influenced by each of these functional domains. Within the respective sections of the figure, the potential neurobiological targets for
each functional domain identified by this systematic review are highlighted in the boxes. The absence of any neurobiological targets in the
physical health section of the figure reflects the lack of investigation into this particular functional domain emphasising the need for more
research into this area. The clinical syndrome section is the most populated which reflects the predominant focus in the literature on this
particular domain. Despite less focus on the remaining three functional domains, the evidence for potential neurobiological targets for these
areas is promising for clinical utility and future research
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those with identified weaknesses in these areas are likely
to require more intensive intervention targeted at these
deficits to improve this functional domain. Such treat-
ment practise has demonstrated clinical utility for im-
proving memory performance in adult groups with
affective disorders [147]. Moreover, cognitive training
was comparable to pharmacological treatment for im-
proving the depression state, whilst also associated with
additional benefits such as, no adverse side effects, im-
proved levels of anxiety, and better academic perform-
ance [148]. Cognitive training may slow or prevent the
impact of cognitive impairment on the social and eco-
nomic participation domain for young people with an
emerging affective disorder.
Notably, the common indicators of social and eco-
nomic functioning in the reviewed studies varied
greatly with some measures (e.g. SOFAS, academic
grades) being more useful than others (e.g. GAF) that
conflate symptoms and functioning. Of the reviewed
studies, there was a lack of focus on social function-
ing and the relationship with certain neurobiological
parameters. The only study to specifically examine
this relationship identified that HPA dysregulation,
indexed by an enhanced cortisol response during a
social task was predictive of social functioning [104].
Although the aforementioned study was cross sec-
tional, longitudinal evidence supporting the predictive
validity of HPA dysregulation and greater disability
(including social disability), provides further support
for the role of HPA dysregulation in social and eco-
nomic participation [102, 103]. However, it is clear
that the role of HPA functioning is complicated given
its implications in multiple functional domains includ-
ing suicide and self-harm behaviours and clinical
syndrome.
Physical health
Physical health as a functional domain for young people
with mood disorders has been notably understudied
(only three studies met the inclusion criteria) compared
to the other four functional domains. This is not com-
pletely unexpected considering that the majority of
neurobiological modalities (neuropsychology, neuroim-
aging, sleep-wake and circadian biology and neurophysi-
ology) are not recognised as being the traditional
method for investigating this particular domain [149]. Of
note, given that metabolic measures are used to classify
physical health outcomes (i.e. BMI is both a physical
health outcome and a metabolic measure) it was not
deemed appropriate to carry out searches for metabolic
measures and physical health outcomes. Future studies
may look to improve the methods and/or key terms used
to investigate the best available measures to assess and
track physical health outcomes in this population.
Suicide and self-harm behaviours
Studies investigating suicide and self-harm behaviours
spanned across all five neurobiological parameters,
and yielded consistent findings across these parame-
ters. Across studies, those with specific executive
function impairments in the domains of decision-
making and conceptual flexibility appear to be more
likely to engage in suicidal thinking or behaviours.
Therefore, identifying these deficits may be particu-
larly important for recognising at risk patients and
providing effective interventions. Furthermore, our
findings provide converging evidence from different
measures of brain structure and function that suicide
and self-harm behaviours are associated with signifi-
cant disruptions in decision-making ability. The re-
duced ACC volumes and activity in the identified
neuroimaging studies as well as neurophysiological
evidence of lower accuracy at differentiating correct
and incorrect responses on a decision-making task
corroborate the neuropsychological findings regarding
the relationship between suicide and self-harm behav-
iours and impaired decision making and conceptual
flexibility.
Importantly, these findings have major implications
for the assessment and intervention of suicide and
self-harm behaviours. Firstly, decision making ability
should be incorporated into the assessment of young
people with mood and anxiety disorders to stratify
young people on the basis of risk for suicidal and
self-harms behaviours. Whilst, there are certainly
other risk factors involved in suicide and self-harm
behaviours [150, 151], the findings from this review
indicate that decision-making may be a mediator of
suicide and self-harm outcomes. Secondly, cognitive
remediation interventions aimed at improving
decision-making ability in those young people that are
identified as having significant impairments may
prove to be a successful early intervention to reduce
or prevent elevated risk for suicide and self-harm be-
haviours [152].
The relationship between metabolic studies investi-
gating blood cholesterol and suicide and self-harm be-
haviours was another major area identified by this
review. Three studies investigating cholesterol consist-
ently identified an association between suicide and
self-harm behaviours and lower cholesterol levels.
Such findings are consistent with evidence that de-
creased cholesterol levels in the brain may be associ-
ated with reduced synaptic plasticity and impaired
neurobiological functioning [153]. Furthermore, lower
serotoninergic activity has also been associated with
reduced cholesterol and implicated in the affective
disorders [154], which was evident in another meta-
bolic study identified by this review [155]. It has been
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suggested that these changes to cholesterol levels may
be the result of HPA axis dysfunction, however fur-
ther studies are needed to explore these associations
and investigate the treatment implications.
Alcohol and substance use
Converging evidence from neuropsychology, neuroim-
aging and neurophysiology indicate that alcohol use is
associated with global impairments. Unsurprisingly, all
the neuroimaging studies suggest that widespread im-
pairment across frontal and temporal areas of the
brain are associated with alcohol and substance use.
Specifically, reduced brain volume and function are
particularly prominent in these areas and these results
reflect the findings of neuropsychological and neuro-
physiology studies that suggest alcohol and substance
use to be associated with cognitive impairments and
poor attention. Independently each individual study’s
limitation of small sample sizes and lack of replica-
tion limit their clinical applicability, however together
the evidence points to similar phenomena.
An important issue is to determine the how these
findings can be used to understand the risk factors
associated with alcohol and substance use. Many of
the impairments may be the result of alcohol and
substance use rather than a mediating factor involved
in the risk of engaging in these behaviours. These
problems have major implications in terms of assess-
ment and intervention. Whilst, the aforementioned
neuroimaging, neuropsychology and neurophysiology
studies may be useful for tracking changes in the ef-
fects of these behaviours overtime, it is still unclear
what assessment measures may be particularly useful
in the early identification of individuals at risk for en-
gaging in these harmful behaviours. More specific longi-
tudinal studies before young people engage in alcohol
and substance use are needed to differentiate between
pre-existing and subsequent effects of alcohol and sub-
stance use. These longitudinal investigations will help
model the role that risk factors such as risk taking, im-
pulsivity, social occupational factors and decision-
making play in the development of poorer alcohol and
substance use outcomes.
Clinical syndrome
The final functional domain addressed by this review
has been extensively reviewed elsewhere [131, 144], and
therefore we provide an overview of these findings spe-
cific to young people and in the context of the other
four functional domains. The primary focus of this par-
ticular domain is to identify features of the clinical syn-
drome that may help characterise a young person’s
illness phenotype and/or stage of illness [25, 156]. The
majority of studies identified by this review utilised case-
control methods to investigate the neurobiological char-
acteristics that separate discrete diagnostic cases from
healthy controls, however these distinctions often pro-
vide limited clinically useful information. Those studies
that sought to describe how specific neurobiological
characteristics are related to illness severity (or per-
haps more importantly, employed a case-case control
method to delineate between cases) were particularly
useful for identifying neurobiological or neurocognitive
risk factors of poorer illness trajectories. Using a multi
parameter approach, this review has been able to
collate evidence that covers a number of ‘columns’ in
the RDoC matrix (i.e. circuits, physiology, behaviours)
to study the pathophysiological drivers of each func-
tional domain, which is crucial for identifying treat-
ment targets [157].
This review has provided evidence to indicate that ver-
bal memory problems may be an early indicator associ-
ated with the emergence of depression since these
deficits were evident in young people with depression,
not identified as MDD, and the emergence of depressive
symptoms in a community sample) [44, 45]. However,
for those young people with more persistent MDD and
more severe depression or anxiety symptoms executive
function deficits seem to be more prominent. Similarly,
another line of evidence emerging from this review indi-
cates that greater illness severity is associated with
greater reductions in the ACC, a prefrontal brain region
associated with executive function. Considering the
previously discussed results regarding the relationship
between executive function, and another two functional
domains (i.e. social and economic participation and
suicide and self-harm behaviours), this reiterates the
role of executive function as a mediating factor that is
associated with poorer illness outcomes across mul-
tiple functional domains that should be a clear treat-
ment target at both a brain circuit and behaviour level.
The benefits of targeting neuropsychological function
are made clear by treatment studies that have shown
that improved cognitive function following a form of
treatment, namely, TMS or pharmacological, has
improve hallmark symptoms in both bipolar and de-
pression. Again, this is reiterated by evidence from
neuroimaging that treatments increasing ACC function
are associated with clinical improvements in depres-
sion and bipolar.
The role of comorbid anxiety in depression and bipo-
lar disorder is notable and associated with a substantial
increase in morbidity and mortality [158–160]. From a
circuitry point of view, the amygdala is one of the pri-
mary brain regions in a broader network that is involved
in depression and anxiety [131, 132]. Specifically, evi-
dence from this review indicates that increased amygdala
volumes are associated with increased anxiety symptom
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severity in MDD as well as a diagnosis of GAD, reiterat-
ing theories that these conditions share similar patho-
physiology that cuts across diagnostic boundaries [161].
Importantly, other neuroimaging work utilising fMRI
has demonstrated that heightened amygdala activity is
associated with both depression and anxiety [132]. This
is evidenced by the neurophysiology study identified by
this review whereby successful CBT treatment for anx-
iety disorder was associated with a reduction in anxiety
symptoms and the startle response, another index of
amygdala reactivity [128]. Together these findings impli-
cate the amygdala as a treatment target that may reduce
neurobiological substrates of anxiety, commonly impli-
cated in the emergence of depression and a problematic
feature in bipolar disorder. To reiterate the value of
amygdala reactivity as a treatment target for anxiety in
affective disorders, studies in the present review demon-
strated that reduced amygdala activation to negative
emotional stimuli, either using pharmacological treat-
ments or CBT, were associated with clinical improve-
ment in both bipolar and anxiety disorders.
From the sleep-wake and circadian biology studies,
sleep dysfunction and cortisol secretion have consist-
ently demonstrated a relationship with the clinical syn-
drome features that allude to differential illness
trajectories. For example, sleep dysfunction, charac-
terised by a number of different sleep parameters, was
not only associated with the presence of a discrete de-
pressive or bipolar illness, but similar dysfunctions were
also evident in those with hypomanic or attenuated syn-
dromes. This is a critical finding since it presents sleep
dysfunction as a primary treatment target to prevent ill-
ness progression in these affective illnesses. Similarly, in-
creased cortisol secretion was consistently implicated in
the emergence of depression [102, 108–110, 112], whilst
two metabolic studies suggest that increased BMI is as-
sociated with the chronic course of mood disorders
[140, 162]. Neurobiologically these findings implicate
HPA dysfunction as being a core feature involved in
mood disorders, and so interventions aimed at improv-
ing the deficits in these brain circuits may be useful to
address these clinical outcomes [163].
Moving towards greater clinical translation
One of the clear problems identified by this systematic
review is the lack of consistently used patient groups
and assessment measures. For any given functional do-
main, multiple self-report or clinician rated scales, neu-
roimaging techniques, and cognitive tests were
implemented that often assess the same or similar out-
comes, whilst the selection of patient groups varies dra-
matically for each study. This fundamentally limits the
capacity for strong comparisons to be made between
studies, or arrive at meaningful and clinically relevant
conclusions. For the field of psychiatry to make new
ground regarding the underlying neurobiology of psy-
chopathology and its associated outcomes major consoli-
dation of the common standardised measures for these
key functional domains and neurobiological parameters
should be implemented. Admittedly differences in scien-
tific or clinical motivations will affect the widespread
adoption of common measures, however much like the
RDoC initiatives focus on key neurobiological domains
of interest similar efforts should be made to maximise
the standardised measurement of the key functional do-
mains of interest across multiple diagnostic groups in
clinical and research settings. In doing this review, we
have provided an overview of the essential functional do-
mains and current neurobiological evidence associated
with these domains, the next step will be to outline the
standard measures that should be drawn upon to pro-
mote better consolidation of findings in the psychiatric
and neurobiological study of mood and anxiety
disorders.
The lack of emphasis on all of these key functional do-
mains and their role in disorder onset, persistence and
impact from a publication, reporting and/or research
priority point of view is problematic for the clinical
translation of psychiatric research. Our study highlights
this pertinent issue so that future research may better
account for these factors and their relationship to key
neurobiological parameters and disorders to improve
our understanding of how these functional domains
interact or relate to mental illness trajectories.
Limitations and future directions
Some limitations of this review should be considered.
First, few studies investigated a particular functional do-
main (i.e. physical health) or utilised particular neurobio-
logical parameters, namely sleep-wake and circadian
biology or metabolic, which limits the synthesis of these
findings and caution is advised when interpreting these
results. Secondly, the restricted use of search terms for
the functional domains or neurobiological parameters
may have limited the identification of key studies, par-
ticularly favouring studies reporting current primary dis-
orders rather than lifetime diagnoses. Best efforts were
made to be inclusive of as many studies as possible to
carry out a complete overview of the literature, however
future studies should look to expand on this work by
adding key search terms that may have been missed to
further the advancement of this growing literature focus-
ing on the functional domains of mood and anxiety dis-
orders in young people. While we focused on RDoC
levels of analysis that correspond to ‘circuits’, ‘physiology’,
‘behaviour’, and ‘self-report’, future studies may want to
include levels of analysis that include genetics, molecules
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and cells for a deeper understanding of these neurobio-
logical factors.
Furthermore, future researchers may want to consider
including borderline personality disorder into these in-
vestigations, given its significant affective component
and relationship with these primary mood and anxiety
disorders. Limitations associated with the systematic re-
view process should be considered when interpreting the
present findings, namely the use of one independent re-
searcher for study selection and lack of a systematic risk
of assessment bias since these may have impacted on the
reliability and validity of data synthesis. Finally, the wide
age range selected for this study is an important caveat
that should be addressed in future studies since there
are significant developmental/neurobiological changes
during this dynamic period of brain development with
respect to grey (e.g. pruning) and white (myelination;
connectivity) matter processes.
Conclusions
Mood and anxiety disorders are especially difficult to
characterise and treat in young people (age 12 – 30
years) when confounds of normal development and
changing environmental influences are prominent. This
review identified a predominant focus in the literature
on the clinical syndrome, which in our view does not ad-
equately address key individual characteristics, such
as suicide and self-harm behaviours or alcohol and sub-
stance use, that are involved in disability and persistent
illness. Based on the synthesis of results from multiple
neurobiological modalities, we provide a detailed sum-
mary of how the clinical utility of neurobiological mea-
sures may be improved by focussing on personalised
assessment of these additional functional outcomes. We
suggest that a shift in focus towards characterising the
mechanisms that underlie and/or mediate multiple func-
tional domains will optimise personalised interventions
and improve illness trajectories.
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